

# MIV Global Medtech Fund

Sub-Fund of an investment company with variable capital SICAV



## Monthly report November 2024

Marketing document for private and institutional investors

### Facts Fund class I1

Net Asset Value per Fund share CHF	2'760.85
Assets CHF m (all Fund classes)	1'984
Investment level	99%
Liquidity	1%

### Industry breakdown

Ophthalmology	12%
Hospital Equipment	10%
Surgical Instruments	7%
Orthopaedics	7%
Diabetes	7%
In-vitro Diagnostics	7%
Disposable Medical Supplies	6%
Endoscopy	5%
Interventional Cardiology	4%
Other Medical Technology Sectors	34%


### Holdings

Abbott Laboratories	10%	ResMed	3%
Stryker	10%	IDEXX Laboratories	3%
Boston Scientific	10%	GE HealthCare	3%
Intuitive Surgical	10%	DexCom	3%
Medtronic	5%	CooperCompanies	2%
EssilorLuxottica	4%	Steris	2%
Alcon	4%	Align Technology	2%
Edwards Lifesciences	4%	Insulet	2%
Becton Dickinson	4%	Hologic	2%
HOYA	4%	13 small holdings	14%

### Currency breakdown

USD	78%	JPY	5%
CHF	8%	DKK	2%
EUR	6%	GBP	2%

### Performance Fund class I1 CHF



### Important legal information

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

Performance in CHF	November	2024	1 year	3 years	5 years	10 years	Inception
MIV Global Medtech Fund I1	5.5%	17.6%	21.8%	-7.1%	12.1%	131.6%	353.6%
Benchmark *	5.1%	18.8%	22.6%	-3.9%	21.9%	157.4%	309.6%
MSCI World Index	6.6%	27.5%	29.5%	22.6%	58.3%	138.4%	219.2%
			12.19-11.20	12.20-11.21	12.21-11.22	12.22-11.23	12.23-11.24
MIV Global Medtech Fund I1			3.1%	17.1%	-18.8%	-6.1%	21.8%
Benchmark *			8.9%	16.4%	-16.7%	-5.9%	22.6%
MSCI World Index			3.7%	24.5%	-8.2%	3.1%	29.5%

\* MSCI World Healthcare Equipment & Supplies

### Company Headlines

At the beginning of November, Donald Trump was elected as the new US president. He has appointed Robert F. Kennedy as Health Secretary. Kennedy has raised eyebrows in the past and during the election with controversial statements on vaccination and the pharmaceutical – but not the medical devices – industry. Generally speaking, medtech is not so much in the focus of politicians as the pharmaceutical industry, as the latter generates a much larger portion of healthcare costs, is regulated more strictly via an approval process and patents and regularly attracts attention with substantial price increases. In contrast to migration and economic policy, health is not a key topic for Donald Trump. During his administration we therefore do not anticipate any major reforms for health policy in general or any negative consequences for the medical device industry in particular. During Trump's first term in office, the medtech industry also showed that it was able to react flexibly to new customs duties.

US-based **Stryker** again beat expectations with its results for the third quarter of 2024, which were published at the end of October. Both Orthopaedics and MedSurg (hospital equipment, endoscopy, surgical instruments) & Neurotechnology produced impressive performances. Organic revenue growth amounted to 11.5%, with increased volumes contributing 10.3 percentage points and higher prices 1.2 percentage points. Management highlighted the high patient volumes, continued strong demand in the area of hospital equipment and the record number of interactive Mako robotic arm installations. Stryker's strong level of innovation has enabled it to steadily improve its market share over the years, thus achieving above-average growth rates. The firm is in an attractive product cycle with numerous launches. The forecast published in January for organic revenue growth of 7.5% to 9.0% was improved to between 9.5% and 10% by October. The growth bandwidth for adjusted earnings per share was increased to between 13% and 14%, which should equal the strong previous year.

**GE Healthcare Technologies**, based in Chicago, Illinois, was spun off as an independent company from General Electric in January 2023. It offers a wide range of medical imaging solutions, patient monitoring systems and pharmaceutical diagnostics. During the reporting month it presented its growth strategy and targets for the three-year period to 2028 at its Investor Day in New York City. CEO Peter Arduini and CFO Jay Saccaro emphasised the significance of innovation and digital solutions, particularly in the field of artificial intelligence (AI) and cloud technologies. The targets include annual organic revenue growth in the mid-single-digit range, considerable margin increases and a rise in earnings in the high single-digit to low double-digit percentage range. The plan is to use the very attractive cash flow for value-adding measures.

## Investments in medical devices

### Investment Strategy

The MIV Global Medtech Fund invests globally in listed medical device companies. The investment process is based on a combined top-down / bottom-up approach. Against the background of the particular macroeconomic environment, the most interesting markets and companies are determined based on an intensive primary analysis. Alongside an attractive valuation, a strong market position, good growth potential, excellent products, sustainable profitability and high-quality management are the decisive parameters for investment. The consideration of sustainability criteria (ESG) is integrated in the research, analysis and investment process. Risks are managed by means of portfolio diversification. The portfolio of the MIV Global Medtech Fund is structured more defensively or cyclically in the best possible anticipation of economic trends, with a view to achieving a higher return than the benchmark and the general market indices.

### Benefits

Owing to demographic trends and the desire for quality of life and mobility, the medical device industry is a long-term growth market. Emerging markets will have a positive impact on the medical device industry's future growth thanks to the state-backed expansion of their healthcare systems. Medical device suppliers' priority is the development of innovative, minimally invasive products. These are beneficial for patients and cost efficient for the healthcare system due to shorter convalescence periods. Most interesting from an investor's perspective are the industry's high growth rates, above-average profitability and oligopolistic market structures with their high entry barriers for new competitors. Even in a demanding environment, significant product innovations continue to offer attractive growth prospects.

### Risks

The MIV Global Medtech Fund invests in equity securities and may therefore be subject to high fluctuations in value. For this reason, a medium-term to long-term investment horizon and corresponding risk tolerance and capacity are required for an investment into this Sub-Fund. As the MIV Global Medtech Fund pursues an active management style, the Sub-Fund's performance can deviate substantially from that of its reference index. The focus on equity securities of global medical device companies potentially exposes the Sub-Fund to additional sector-specific risks and currency risks. The Sub-Fund may, for the purpose of hedging and the efficient management of the portfolio, make use of derivatives, which can lead to additional risks (particularly counter party risk). All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions.

### Sustainability profile - ESG

MIV Asset Management identifies, monitors and mitigates ESG risks that are, or could become, material to the performance of medical technology companies. The approach is based on the following factors:

- **Integration:** The consideration of sustainability criteria (ESG) is integrated into the research, analysis and investment process. The Fund invests in companies with a good ESG profile. The Fund does not invest in companies with a Sustainalytics ESG Risk Rating above 40 (severe) as well as a Sustainalytics Controversy Score above 4 (high).
- **Exclusion:** The Fund excludes investments in companies, that are not compliant with global norms (OECD Guidelines for Multinational Enterprises, UN Guiding Principles for Business and Human Rights, International Labour Organization's Fundamental Principles) as well as investments in controversial industries (particularly conventional and controversial weapons).
- **Sustainable Investments:** A minimum portion of 33% of assets is invested in Sustainable Investments with a social objective (contribution to UN Sustainable Development Goals).
- **Dialogue:** Close and regular contact with the management of actual and potential investments, amongst other, with the goal of improving ESG practices and disclosure at these companies.
- **Ownership rights:** Exercise of MIV Global Medtech Fund's voting rights delegated to the ISS proxy with Sustainability Policy. In case of controversial decisions, MIV Asset Management gets directly involved.

- The MIV Global Medtech Fund is classified as a financial product under **EU SFDR Article 8**
- MIV Asset Management is a signatory to the **UN Principles for Responsible Investment**
- The MIV Global Medtech Fund's investments support **UN Sustainable Development Goals, in particular no. 1, 3, 5, 8 and 10**
- MIV Asset Management works together with the **proxy ISS with Sustainability Policy**
- The MIV Global Medtech Fund has an **above-average MSCI ESG Score (6.5) and MSCI ESG Rating (A)**
- The MIV Global Medtech Fund has an **above-average Sustainalytics ESG profile**

### Glossary

Benchmark	An index, which is used as a reference for the measurement of the performance of the Fund.
Inception	Launch date of the Fund and/or the Fund class.
Management fee	Portfolio manager's fee for the management and the distribution of the Fund.
NAV	Net Asset Value: total Fund assets divided by total number of Fund shares outstanding.
TER	Total Expense Ratio: sum of all fees and costs, which are charged to the Fund on a continuous basis.

## Investments in medical devices

### Information

Website	www.mivglobalmedtech.ch
Legal structure	Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law
Fund class	I1 (CHF) accumulation / ISIN: LU0329631377 / Swiss Valor Number: 3535028 / WKN: A0NETS
Subscription/redemption	On every bank working day in Luxembourg until 3.45 p.m. at net asset value (no calculation of net asset values on bank/stock exchange holidays in Luxembourg and/or the US)
Management fee	0.8% p.a.
Total Expense Ratio (TER) as of 30.6.2024	0.97%
Launch of fund	11 March 2008
Close of financial year	30 June
Benchmark	MSCI World Healthcare Equipment & Supplies
Reporting of the Portfolio manager	Monthly, semester and yearly report
Fund price monitoring	www.mivglobalmedtech.ch / www.swissfunddata.ch / www.fundinfo.com Bloomberg: VARMV11 LX / Reuters: LU0329631377.LUF / Neue Zürcher Zeitung
Portfolio manager	MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, info@mivglobalmedtech.ch Contact: Christoph Gubler, Giuseppe Di Benedetto, Christoph Gretler, Phone +41 44 253 64 11
Management company	Vontobel Asset Management S.A., 18, rue Erasme, L-1468 Luxembourg
Representative for Switzerland	Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich
Custodian/Administrator	State Street Bank International GmbH, 49, Avenue J.F. Kennedy, L-1855 Luxembourg
Auditor	Ernst & Young S.A., 35E, Avenue J.F. Kennedy, L-1855 Luxembourg
Minimum subscription	CHF 500'000
Admissions to distribution	Switzerland, Germany, Austria, Liechtenstein, Luxembourg, France, Italy, Spain, United Kingdom, Netherlands, Finland, Norway, Sweden, Singapore (restricted scheme)
Distribution restrictions	USA / US persons

### Important legal information

MIV Global Medtech Fund is a Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law. This document is for information purposes only and nothing contained in this document should constitute a solicitation, or offer, or recommendation, to buy or sell any investment instruments, to effect any transactions, or to conclude any legal act of any kind whatsoever. This document has been produced by MIV Asset Management AG. It is explicitly not the result of a financial analysis and therefore the "Directives on the Independence of Financial Research" of the Swiss Bankers Association is not applicable. Although MIV Asset Management AG believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report. Any companies described in this document may or may not currently represent a position in the portfolio of the MIV Global Medtech Fund. Any projections, forecasts or estimates contained in this document are based on a variety of estimates and assumptions. There can be no assurance that the estimates or assumptions made will prove accurate, and actual results may differ materially.

Subscriptions of shares of the Sub-Fund should in any event be made solely on the basis of the current sales prospectus, the current Key Information Documents (KIDs), the current articles of association and the most recent annual and semi-annual reports of Variopartner SICAV. For more details regarding the potential risks of an investment in Sub-Funds of Variopartner SICAV, please refer to the current sales prospectus. Interested parties may obtain the abovementioned documents free of charge from the portfolio manager: MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, the representative for Switzerland: Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich, the paying agent in Switzerland: Bank Vontobel AG, Gotthardstrasse 43, CH-8022 Zurich, the European facilities agent for Germany, Finland, France, Italy, the Netherlands, Norway, Sweden and Spain: PwC Société coopérative – GFD, 2, rue Gerhard Mercator B.P. 1443, L-1014 Luxembourg, [lu\\_pwc.gfd.facsvs@pwc.com](mailto:lu_pwc.gfd.facsvs@pwc.com), the financial and central agent in France: BNP Paribas S.A., 16, Boulevard des Italiens, F-75009 Paris, the Austrian Facility: Erste Bank der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna, the information agent in Liechtenstein: LLB Fund Services AG, Äulestrasse 80, FL-9490 Vaduz, the paying agents in Italy: Banca Sella Holding S.p.A., Piazza Gaudenzio Sella, 1, I-13900 Biella, Allfunds Bank, S.A.U., Via Bocchetto, 6, I-20123 Milan, the facilities agent for the United Kingdom: Carne Financial Services (UK) LLP, 29-30 Cornhill, London EC3V 3ND, and from the offices of the Fund: Variopartner SICAV, 49, Avenue J.F. Kennedy, L-1855 Luxembourg. They may also be downloaded from the website [www.mivglobalmedtech.com](http://www.mivglobalmedtech.com).

Further information on the distribution of the fund's shares in an official language of the respective distribution country can be found on the corresponding website:

Germany	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-de">https://gfdplatform.pwc.lu/facilities-agent/view/vs-de</a>
Finland	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi</a>
France	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr</a>
Italy	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-it">https://gfdplatform.pwc.lu/facilities-agent/view/vs-it</a>
Netherlands	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl">https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl</a>
Norway	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-no">https://gfdplatform.pwc.lu/facilities-agent/view/vs-no</a>
Sweden	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv">https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv</a>
Spain	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-es">https://gfdplatform.pwc.lu/facilities-agent/view/vs-es</a>

This Sub-Fund is registered with the Financial Conduct Authority (FCA) for public distribution in the United Kingdom.

This Sub-Fund is not available to retail investors in Singapore. It is accepted as restricted scheme by the Monetary Authority of Singapore (MAS) and may only be offered to certain prescribed persons on certain conditions as provided in the "Securities and Futures Act", Chapter 289 of Singapore.

This Sub-Fund is not authorised by the Securities and Futures Commission of Hong Kong. It may only be offered to those investors qualifying as professional investors under the Securities and Futures Ordinance. The contents of this document have not been reviewed by any regulatory authority in Hong Kong.

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

# MIV Global Medtech Fund

Sub-Fund of an investment company with variable capital SICAV



Monthly report November 2024

Marketing document for private and institutional investors

## Facts Fund class I2

Net Asset Value per Fund share EUR	2'967.03
Assets EUR m (all Fund classes)	2'132
Investment level	99%
Liquidity	1%

## Industry breakdown

Ophthalmology	12%
Hospital Equipment	10%
Surgical Instruments	7%
Orthopaedics	7%
Diabetes	7%
In-vitro Diagnostics	7%
Disposable Medical Supplies	6%
Endoscopy	5%
Interventional Cardiology	4%
Other Medical Technology Sectors	34%


## Holdings

Abbott Laboratories	10%	ResMed	3%
Stryker	10%	IDEXX Laboratories	3%
Boston Scientific	10%	GE HealthCare	3%
Intuitive Surgical	10%	DexCom	3%
Medtronic	5%	CooperCompanies	2%
EssilorLuxottica	4%	Steris	2%
Alcon	4%	Align Technology	2%
Edwards Lifesciences	4%	Insulet	2%
Becton Dickinson	4%	Hologic	2%
HOYA	4%	13 small holdings	14%

## Currency breakdown

USD	78%	JPY	5%
CHF	8%	DKK	2%
EUR	6%	GBP	2%

## Performance Fund class I2 EUR



## Important legal information

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

Performance in EUR	November	2024	1 year	3 years	5 years	10 years	Inception
MIV Global Medtech Fund I2	6.4%	17.5%	24.2%	4.0%	32.8%	199.0%	512.1%
Benchmark *	6.1%	18.7%	25.1%	7.6%	44.4%	232.3%	537.6%
MSCI World Index	7.5%	27.4%	32.1%	37.2%	87.4%	207.8%	422.4%
			12.19-11.20	12.20-11.21	12.21-11.22	12.22-11.23	12.23-11.24
MIV Global Medtech Fund I2			4.9%	21.7%	-13.8%	-2.9%	24.2%
Benchmark *			10.8%	21.1%	-11.6%	-2.7%	25.1%
MSCI World Index			5.6%	29.4%	-2.6%	6.6%	32.1%

\* MSCI World Healthcare Equipment & Supplies

## Company Headlines

At the beginning of November, Donald Trump was elected as the new US president. He has appointed Robert F. Kennedy as Health Secretary. Kennedy has raised eyebrows in the past and during the election with controversial statements on vaccination and the pharmaceutical – but not the medical devices – industry. Generally speaking, medtech is not so much in the focus of politicians as the pharmaceutical industry, as the latter generates a much larger portion of healthcare costs, is regulated more strictly via an approval process and patents and regularly attracts attention with substantial price increases. In contrast to migration and economic policy, health is not a key topic for Donald Trump. During his administration we therefore do not anticipate any major reforms for health policy in general or any negative consequences for the medical device industry in particular. During Trump's first term in office, the medtech industry also showed that it was able to react flexibly to new customs duties.

US-based **Stryker** again beat expectations with its results for the third quarter of 2024, which were published at the end of October. Both Orthopaedics and MedSurg (hospital equipment, endoscopy, surgical instruments) & Neurotechnology produced impressive performances. Organic revenue growth amounted to 11.5%, with increased volumes contributing 10.3 percentage points and higher prices 1.2 percentage points. Management highlighted the high patient volumes, continued strong demand in the area of hospital equipment and the record number of interactive Mako robotic arm installations. Stryker's strong level of innovation has enabled it to steadily improve its market share over the years, thus achieving above-average growth rates. The firm is in an attractive product cycle with numerous launches. The forecast published in January for organic revenue growth of 7.5% to 9.0% was improved to between 9.5% and 10% by October. The growth bandwidth for adjusted earnings per share was increased to between 13% and 14%, which should equal the strong previous year.

**GE Healthcare Technologies**, based in Chicago, Illinois, was spun off as an independent company from General Electric in January 2023. It offers a wide range of medical imaging solutions, patient monitoring systems and pharmaceutical diagnostics. During the reporting month it presented its growth strategy and targets for the three-year period to 2028 at its Investor Day in New York City. CEO Peter Arduini and CFO Jay Saccaro emphasised the significance of innovation and digital solutions, particularly in the field of artificial intelligence (AI) and cloud technologies. The targets include annual organic revenue growth in the mid-single-digit range, considerable margin increases and a rise in earnings in the high single-digit to low double-digit percentage range. The plan is to use the very attractive cash flow for value-adding measures.

## Investments in medical devices

### Investment Strategy

The MIV Global Medtech Fund invests globally in listed medical device companies. The investment process is based on a combined top-down / bottom-up approach. Against the background of the particular macroeconomic environment, the most interesting markets and companies are determined based on an intensive primary analysis. Alongside an attractive valuation, a strong market position, good growth potential, excellent products, sustainable profitability and high-quality management are the decisive parameters for investment. The consideration of sustainability criteria (ESG) is integrated in the research, analysis and investment process. Risks are managed by means of portfolio diversification. The portfolio of the MIV Global Medtech Fund is structured more defensively or cyclically in the best possible anticipation of economic trends, with a view to achieving a higher return than the benchmark and the general market indices.

### Benefits

Owing to demographic trends and the desire for quality of life and mobility, the medical device industry is a long-term growth market. Emerging markets will have a positive impact on the medical device industry's future growth thanks to the state-backed expansion of their healthcare systems. Medical device suppliers' priority is the development of innovative, minimally invasive products. These are beneficial for patients and cost efficient for the healthcare system due to shorter convalescence periods. Most interesting from an investor's perspective are the industry's high growth rates, above-average profitability and oligopolistic market structures with their high entry barriers for new competitors. Even in a demanding environment, significant product innovations continue to offer attractive growth prospects.

### Risks

The MIV Global Medtech Fund invests in equity securities and may therefore be subject to high fluctuations in value. For this reason, a medium-term to long-term investment horizon and corresponding risk tolerance and capacity are required for an investment into this Sub-Fund. As the MIV Global Medtech Fund pursues an active management style, the Sub-Fund's performance can deviate substantially from that of its reference index. The focus on equity securities of global medical device companies potentially exposes the Sub-Fund to additional sector-specific risks and currency risks. The Sub-Fund may, for the purpose of hedging and the efficient management of the portfolio, make use of derivatives, which can lead to additional risks (particularly counter party risk). All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions.

### Sustainability profile - ESG

MIV Asset Management identifies, monitors and mitigates ESG risks that are, or could become, material to the performance of medical technology companies. The approach is based on the following factors:

- **Integration:** The consideration of sustainability criteria (ESG) is integrated into the research, analysis and investment process. The Fund invests in companies with a good ESG profile. The Fund does not invest in companies with a Sustainalytics ESG Risk Rating above 40 (severe) as well as a Sustainalytics Controversy Score above 4 (high).
- **Exclusion:** The Fund excludes investments in companies, that are not compliant with global norms (OECD Guidelines for Multinational Enterprises, UN Guiding Principles for Business and Human Rights, International Labour Organization's Fundamental Principles) as well as investments in controversial industries (particularly conventional and controversial weapons).
- **Sustainable Investments:** A minimum portion of 33% of assets is invested in Sustainable Investments with a social objective (contribution to UN Sustainable Development Goals).
- **Dialogue:** Close and regular contact with the management of actual and potential investments, amongst other, with the goal of improving ESG practices and disclosure at these companies.
- **Ownership rights:** Exercise of MIV Global Medtech Fund's voting rights delegated to the ISS proxy with Sustainability Policy. In case of controversial decisions, MIV Asset Management gets directly involved.

- The MIV Global Medtech Fund is classified as a financial product under **EU SFDR Article 8**
- MIV Asset Management is a signatory to the **UN Principles for Responsible Investment**
- The MIV Global Medtech Fund's investments support **UN Sustainable Development Goals, in particular no. 1, 3, 5, 8 and 10**
- MIV Asset Management works together with the **proxy ISS with Sustainability Policy**
- The MIV Global Medtech Fund has an **above-average MSCI ESG Score (6.5) and MSCI ESG Rating (A)**
- The MIV Global Medtech Fund has an **above-average Sustainalytics ESG profile**

### Glossary

Benchmark	An index, which is used as a reference for the measurement of the performance of the Fund.
Inception	Launch date of the Fund and/or the Fund class.
Management fee	Portfolio manager's fee for the management and the distribution of the Fund.
NAV	Net Asset Value: total Fund assets divided by total number of Fund shares outstanding.
TER	Total Expense Ratio: sum of all fees and costs, which are charged to the Fund on a continuous basis.

## Investments in medical devices

### Information

Website	www.mivglobalmedtech.ch
Legal structure	Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law
Fund class	I2 (EUR) accumulation / ISIN: LU0329631708 / Swiss Valor Number: 3535030 / WKN: A0NETT
Subscription/redemption	On every bank working day in Luxembourg until 3.45 p.m. at net asset value (no calculation of net asset values on bank/stock exchange holidays in Luxembourg and/or the US)
Management fee	0.8% p.a.
Total Expense Ratio (TER) as of 30.6.2024	0.97%
Launch of fund	11 March 2008
Launch of fund class I2	16 June 2010
Close of financial year	30 June
Benchmark	MSCI World Healthcare Equipment & Supplies
Reporting of the Portfolio manager	Monthly, semester and yearly report
Fund price monitoring	www.mivglobalmedtech.ch / www.swissfunddata.ch / www.fundinfo.com Bloomberg: VARMVI2 LX / Reuters: LU0329631708.LUF / Neue Zürcher Zeitung
Portfolio manager	MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, info@mivglobalmedtech.ch Contact: Christoph Gubler, Giuseppe Di Benedetto, Christoph Greter, Phone +41 44 253 64 11
Management company	Vontobel Asset Management S.A., 18, rue Erasme, L-1468 Luxembourg
Representative for Switzerland	Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich
Custodian/Administrator	State Street Bank International GmbH, 49, Avenue J.F. Kennedy, L-1855 Luxembourg
Auditor	Ernst & Young S.A., 35E, Avenue J.F. Kennedy, L-1855 Luxembourg
Minimum subscription	EUR 500'000
Admissions to distribution	Switzerland, Germany, Austria, Liechtenstein, Luxembourg, France, Italy, Spain, United Kingdom, Netherlands, Finland, Norway, Sweden, Singapore (restricted scheme)
Distribution restrictions	USA / US persons

### Important legal information

MIV Global Medtech Fund is a Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law. This document is for information purposes only and nothing contained in this document should constitute a solicitation, or offer, or recommendation, to buy or sell any investment instruments, to effect any transactions, or to conclude any legal act of any kind whatsoever. This document has been produced by MIV Asset Management AG. It is explicitly not the result of a financial analysis and therefore the "Directives on the Independence of Financial Research" of the Swiss Bankers Association is not applicable. Although MIV Asset Management AG believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report. Any companies described in this document may or may not currently represent a position in the portfolio of the MIV Global Medtech Fund. Any projections, forecasts or estimates contained in this document are based on a variety of estimates and assumptions. There can be no assurance that the estimates or assumptions made will prove accurate, and actual results may differ materially.

Subscriptions of shares of the Sub-Fund should in any event be made solely on the basis of the current sales prospectus, the current Key Information Documents (KIDs), the current articles of association and the most recent annual and semi-annual reports of Variopartner SICAV. For more details regarding the potential risks of an investment in Sub-Funds of Variopartner SICAV, please refer to the current sales prospectus. Interested parties may obtain the abovementioned documents free of charge from the portfolio manager: MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, the representative for Switzerland: Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich, the paying agent in Switzerland: Bank Vontobel AG, Gotthardstrasse 43, CH-8022 Zurich, the European facilities agent for Germany, Finland, France, Italy, the Netherlands, Norway, Sweden and Spain: PwC Société coopérative – GFD, 2, rue Gerhard Mercator B.P. 1443, L-1014 Luxembourg, [lu\\_pwc.gfd.facsvs@pwc.com](mailto:lu_pwc.gfd.facsvs@pwc.com), the financial and central agent in France: BNP Paribas S.A., 16, Boulevard des Italiens, F-75009 Paris, the Austrian Facility: Erste Bank der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna, the information agent in Liechtenstein: LLB Fund Services AG, Äulestrasse 80, FL-9490 Vaduz, the paying agents in Italy: Banca Sella Holding S.p.A., Piazza Gaudenzio Sella, 1, I-13900 Biella, Allfunds Bank, S.A.U., Via Bocchetto, 6, I-20123 Milan, the facilities agent for the United Kingdom: Carne Financial Services (UK) LLP, 29-30 Cornhill, London EC3V 3ND, and from the offices of the Fund: Variopartner SICAV, 49, Avenue J.F. Kennedy, L-1855 Luxembourg. They may also be downloaded from the website [www.mivglobalmedtech.com](http://www.mivglobalmedtech.com).

Further information on the distribution of the fund's shares in an official language of the respective distribution country can be found on the corresponding website:

Germany	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-de">https://gfdplatform.pwc.lu/facilities-agent/view/vs-de</a>
Finland	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi</a>
France	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr</a>
Italy	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-it">https://gfdplatform.pwc.lu/facilities-agent/view/vs-it</a>
Netherlands	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl">https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl</a>
Norway	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-no">https://gfdplatform.pwc.lu/facilities-agent/view/vs-no</a>
Sweden	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv">https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv</a>
Spain	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-es">https://gfdplatform.pwc.lu/facilities-agent/view/vs-es</a>

This Sub-Fund is registered with the Financial Conduct Authority (FCA) for public distribution in the United Kingdom.

This Sub-Fund is not available to retail investors in Singapore. It is accepted as restricted scheme by the Monetary Authority of Singapore (MAS) and may only be offered to certain prescribed persons on certain conditions as provided in the "Securities and Futures Act", Chapter 289 of Singapore.

This Sub-Fund is not authorised by the Securities and Futures Commission of Hong Kong. It may only be offered to those investors qualifying as professional investors under the Securities and Futures Ordinance. The contents of this document have not been reviewed by any regulatory authority in Hong Kong.

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

# MIV Global Medtech Fund

Sub-Fund of an investment company with variable capital SICAV



Monthly report November 2024

Marketing document for private and institutional investors

## Facts Fund class I3

Net Asset Value per Fund share USD	3'134.07
Assets USD m (all Fund classes)	2'252
Investment level	99%
Liquidity	1%

## Industry breakdown

Ophthalmology	12%
Hospital Equipment	10%
Surgical Instruments	7%
Orthopaedics	7%
Diabetes	7%
In-vitro Diagnostics	7%
Disposable Medical Supplies	6%
Endoscopy	5%
Interventional Cardiology	4%
Other Medical Technology Sectors	34%


## Holdings

Abbott Laboratories	10%	ResMed	3%
Stryker	10%	IDEXX Laboratories	3%
Boston Scientific	10%	GE HealthCare	3%
Intuitive Surgical	10%	DexCom	3%
Medtronic	5%	CooperCompanies	2%
EssilorLuxottica	4%	Steris	2%
Alcon	4%	Align Technology	2%
Edwards Lifesciences	4%	Insulet	2%
Becton Dickinson	4%	Hologic	2%
HOYA	4%	13 small holdings	14%

## Currency breakdown

USD	78%	JPY	5%
CHF	8%	DKK	2%
EUR	6%	GBP	2%

## Performance Fund class I3 USD



## Important legal information

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

Performance in USD	November	2024	1 year	3 years	5 years	10 years	Inception
MIV Global Medtech Fund I3	3.6%	12.4%	20.2%	-2.4%	27.2%	153.4%	204.5%
Benchmark *	3.2%	13.5%	21.1%	1.0%	38.3%	181.5%	252.6%
MSCI World Index	4.6%	21.8%	27.8%	28.7%	79.5%	160.8%	188.9%
			12.19-11.20	12.20-11.21	12.21-11.22	12.22-11.23	12.23-11.24
MIV Global Medtech Fund I3			13.8%	14.5%	-21.1%	2.9%	20.2%
Benchmark *			20.2%	13.9%	-19.1%	3.1%	21.1%
MSCI World Index			14.5%	21.8%	-10.9%	13.0%	27.8%

\* MSCI World Healthcare Equipment & Supplies

## Company Headlines

At the beginning of November, Donald Trump was elected as the new US president. He has appointed Robert F. Kennedy as Health Secretary. Kennedy has raised eyebrows in the past and during the election with controversial statements on vaccination and the pharmaceutical – but not the medical devices – industry. Generally speaking, medtech is not so much in the focus of politicians as the pharmaceutical industry, as the latter generates a much larger portion of healthcare costs, is regulated more strictly via an approval process and patents and regularly attracts attention with substantial price increases. In contrast to migration and economic policy, health is not a key topic for Donald Trump. During his administration we therefore do not anticipate any major reforms for health policy in general or any negative consequences for the medical device industry in particular. During Trump's first term in office, the medtech industry also showed that it was able to react flexibly to new customs duties.

US-based **Stryker** again beat expectations with its results for the third quarter of 2024, which were published at the end of October. Both Orthopaedics and MedSurg (hospital equipment, endoscopy, surgical instruments) & Neurotechnology produced impressive performances. Organic revenue growth amounted to 11.5%, with increased volumes contributing 10.3 percentage points and higher prices 1.2 percentage points. Management highlighted the high patient volumes, continued strong demand in the area of hospital equipment and the record number of interactive Mako robotic arm installations. Stryker's strong level of innovation has enabled it to steadily improve its market share over the years, thus achieving above-average growth rates. The firm is in an attractive product cycle with numerous launches. The forecast published in January for organic revenue growth of 7.5% to 9.0% was improved to between 9.5% and 10% by October. The growth bandwidth for adjusted earnings per share was increased to between 13% and 14%, which should equal the strong previous year.

**GE Healthcare Technologies**, based in Chicago, Illinois, was spun off as an independent company from General Electric in January 2023. It offers a wide range of medical imaging solutions, patient monitoring systems and pharmaceutical diagnostics. During the reporting month it presented its growth strategy and targets for the three-year period to 2028 at its Investor Day in New York City. CEO Peter Arduini and CFO Jay Saccaro emphasised the significance of innovation and digital solutions, particularly in the field of artificial intelligence (AI) and cloud technologies. The targets include annual organic revenue growth in the mid-single-digit range, considerable margin increases and a rise in earnings in the high single-digit to low double-digit percentage range. The plan is to use the very attractive cash flow for value-adding measures.

## Investments in medical devices

### Investment Strategy

The MIV Global Medtech Fund invests globally in listed medical device companies. The investment process is based on a combined top-down / bottom-up approach. Against the background of the particular macroeconomic environment, the most interesting markets and companies are determined based on an intensive primary analysis. Alongside an attractive valuation, a strong market position, good growth potential, excellent products, sustainable profitability and high-quality management are the decisive parameters for investment. The consideration of sustainability criteria (ESG) is integrated in the research, analysis and investment process. Risks are managed by means of portfolio diversification. The portfolio of the MIV Global Medtech Fund is structured more defensively or cyclically in the best possible anticipation of economic trends, with a view to achieving a higher return than the benchmark and the general market indices.

### Benefits

Owing to demographic trends and the desire for quality of life and mobility, the medical device industry is a long-term growth market. Emerging markets will have a positive impact on the medical device industry's future growth thanks to the state-backed expansion of their healthcare systems. Medical device suppliers' priority is the development of innovative, minimally invasive products. These are beneficial for patients and cost efficient for the healthcare system due to shorter convalescence periods. Most interesting from an investor's perspective are the industry's high growth rates, above-average profitability and oligopolistic market structures with their high entry barriers for new competitors. Even in a demanding environment, significant product innovations continue to offer attractive growth prospects.

### Risks

The MIV Global Medtech Fund invests in equity securities and may therefore be subject to high fluctuations in value. For this reason, a medium-term to long-term investment horizon and corresponding risk tolerance and capacity are required for an investment into this Sub-Fund. As the MIV Global Medtech Fund pursues an active management style, the Sub-Fund's performance can deviate substantially from that of its reference index. The focus on equity securities of global medical device companies potentially exposes the Sub-Fund to additional sector-specific risks and currency risks. The Sub-Fund may, for the purpose of hedging and the efficient management of the portfolio, make use of derivatives, which can lead to additional risks (particularly counter party risk). All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions.

### Sustainability profile - ESG

MIV Asset Management identifies, monitors and mitigates ESG risks that are, or could become, material to the performance of medical technology companies. The approach is based on the following factors:

- **Integration:** The consideration of sustainability criteria (ESG) is integrated into the research, analysis and investment process. The Fund invests in companies with a good ESG profile. The Fund does not invest in companies with a Sustainalytics ESG Risk Rating above 40 (severe) as well as a Sustainalytics Controversy Score above 4 (high).
- **Exclusion:** The Fund excludes investments in companies, that are not compliant with global norms (OECD Guidelines for Multinational Enterprises, UN Guiding Principles for Business and Human Rights, International Labour Organization's Fundamental Principles) as well as investments in controversial industries (particularly conventional and controversial weapons).
- **Sustainable Investments:** A minimum portion of 33% of assets is invested in Sustainable Investments with a social objective (contribution to UN Sustainable Development Goals).
- **Dialogue:** Close and regular contact with the management of actual and potential investments, amongst other, with the goal of improving ESG practices and disclosure at these companies.
- **Ownership rights:** Exercise of MIV Global Medtech Fund's voting rights delegated to the ISS proxy with Sustainability Policy. In case of controversial decisions, MIV Asset Management gets directly involved.

- The MIV Global Medtech Fund is classified as a financial product under **EU SFDR Article 8**
- MIV Asset Management is a signatory to the **UN Principles for Responsible Investment**
- The MIV Global Medtech Fund's investments support **UN Sustainable Development Goals, in particular no. 1, 3, 5, 8 and 10**
- MIV Asset Management works together with the **proxy ISS with Sustainability Policy**
- The MIV Global Medtech Fund has an **above-average MSCI ESG Score (6.5) and MSCI ESG Rating (A)**
- The MIV Global Medtech Fund has an **above-average Sustainalytics ESG profile**

### Glossary

Benchmark	An index, which is used as a reference for the measurement of the performance of the Fund.
Inception	Launch date of the Fund and/or the Fund class.
Management fee	Portfolio manager's fee for the management and the distribution of the Fund.
NAV	Net Asset Value: total Fund assets divided by total number of Fund shares outstanding.
TER	Total Expense Ratio: sum of all fees and costs, which are charged to the Fund on a continuous basis.



## Investments in medical devices

### Information

Website	www.mivglobalmedtech.ch
Legal structure	Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law
Fund class	<b>I3</b> (USD) accumulation / ISIN: LU0969575645 / Swiss Valor Number: 22479883 / WKN: A1W7RK
Subscription/redemption	On every bank working day in Luxembourg until 3.45 p.m. at net asset value (no calculation of net asset values on bank/stock exchange holidays in Luxembourg and/or the US)
Management fee	0.8% p.a.
Total Expense Ratio (TER) as of 30.6.2024	0.97%
Launch of fund	11 March 2008
Launch of fund class I3	4 November 2013
Close of financial year	30 June
Benchmark	MSCI World Healthcare Equipment & Supplies
Reporting of the Portfolio manager	Monthly, semester and yearly report
Fund price monitoring	www.mivglobalmedtech.ch / www.swissfunddata.ch / www.fundinfo.com Bloomberg: VARI3US LX / Reuters: LU0969575645.LUF / Neue Zürcher Zeitung
Portfolio manager	MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, info@mivglobalmedtech.ch Contact: Christoph Gubler, Giuseppe Di Benedetto, Christoph Greter, Phone +41 44 253 64 11
Management company	Vontobel Asset Management S.A., 18, rue Erasme, L-1468 Luxembourg
Representative for Switzerland	Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich
Custodian/Administrator	State Street Bank International GmbH, 49, Avenue J.F. Kennedy, L-1855 Luxembourg
Auditor	Ernst & Young S.A., 35E, Avenue J.F. Kennedy, L-1855 Luxembourg
Minimum subscription	USD 500'000
Admissions to distribution	Switzerland, Germany, Austria, Liechtenstein, Luxembourg, France, Italy, Spain, United Kingdom, Netherlands, Finland, Norway, Sweden, Singapore (restricted scheme)
Distribution restrictions	USA / US persons

### Important legal information

MIV Global Medtech Fund is a Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law. This document is for information purposes only and nothing contained in this document should constitute a solicitation, or offer, or recommendation, to buy or sell any investment instruments, to effect any transactions, or to conclude any legal act of any kind whatsoever. This document has been produced by MIV Asset Management AG. It is explicitly not the result of a financial analysis and therefore the "Directives on the Independence of Financial Research" of the Swiss Bankers Association is not applicable. Although MIV Asset Management AG believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report. Any companies described in this document may or may not currently represent a position in the portfolio of the MIV Global Medtech Fund. Any projections, forecasts or estimates contained in this document are based on a variety of estimates and assumptions. There can be no assurance that the estimates or assumptions made will prove accurate, and actual results may differ materially.

Subscriptions of shares of the Sub-Fund should in any event be made solely on the basis of the current sales prospectus, the current Key Information Documents (KIDs), the current articles of association and the most recent annual and semi-annual reports of Variopartner SICAV. For more details regarding the potential risks of an investment in Sub-Funds of Variopartner SICAV, please refer to the current sales prospectus. Interested parties may obtain the abovementioned documents free of charge from the portfolio manager: MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, the representative for Switzerland: Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich, the paying agent in Switzerland: Bank Vontobel AG, Gotthardstrasse 43, CH-8022 Zurich, the European facilities agent for Germany, Finland, France, Italy, the Netherlands, Norway, Sweden and Spain: PwC Société coopérative – GFD, 2, rue Gerhard Mercator B.P. 1443, L-1014 Luxembourg, [lu\\_pwc.gfd.facsvs@pwc.com](mailto:lu_pwc.gfd.facsvs@pwc.com), the financial and central agent in France: BNP Paribas S.A., 16, Boulevard des Italiens, F-75009 Paris, the Austrian Facility: Erste Bank der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna, the information agent in Liechtenstein: LLB Fund Services AG, Äulestrasse 80, FL-9490 Vaduz, the paying agents in Italy: Banca Sella Holding S.p.A., Piazza Gaudenzio Sella, 1, I-13900 Biella, Allfunds Bank, S.A.U., Via Bocchetto, 6, I-20123 Milan, the facilities agent for the United Kingdom: Carne Financial Services (UK) LLP, 29-30 Cornhill, London EC3V 3ND, and from the offices of the Fund: Variopartner SICAV, 49, Avenue J.F. Kennedy, L-1855 Luxembourg. They may also be downloaded from the website [www.mivglobalmedtech.com](http://www.mivglobalmedtech.com).

Further information on the distribution of the fund's shares in an official language of the respective distribution country can be found on the corresponding website:

Germany	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-de">https://gfdplatform.pwc.lu/facilities-agent/view/vs-de</a>
Finland	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi</a>
France	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr</a>
Italy	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-it">https://gfdplatform.pwc.lu/facilities-agent/view/vs-it</a>
Netherlands	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl">https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl</a>
Norway	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-no">https://gfdplatform.pwc.lu/facilities-agent/view/vs-no</a>
Sweden	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv">https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv</a>
Spain	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-es">https://gfdplatform.pwc.lu/facilities-agent/view/vs-es</a>

This Sub-Fund is registered with the Financial Conduct Authority (FCA) for public distribution in the United Kingdom.

This Sub-Fund is not available to retail investors in Singapore. It is accepted as restricted scheme by the Monetary Authority of Singapore (MAS) and may only be offered to certain prescribed persons on certain conditions as provided in the "Securities and Futures Act", Chapter 289 of Singapore.

This Sub-Fund is not authorised by the Securities and Futures Commission of Hong Kong. It may only be offered to those investors qualifying as professional investors under the Securities and Futures Ordinance. The contents of this document have not been reviewed by any regulatory authority in Hong Kong.

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

# MIV Global Medtech Fund

Sub-Fund of an investment company with variable capital SICAV



## Monthly report November 2024

Marketing document for private and institutional investors

### Facts Fund class N1

Net Asset Value per Fund share CHF	2'671.17
Assets CHF m (all Fund classes)	1'984
Investment level	99%
Liquidity	1%

### Industry breakdown

Ophthalmology	12%
Hospital Equipment	10%
Surgical Instruments	7%
Orthopaedics	7%
Diabetes	7%
In-vitro Diagnostics	7%
Disposable Medical Supplies	6%
Endoscopy	5%
Interventional Cardiology	4%
Other Medical Technology Sectors	34%


### Holdings

Abbott Laboratories	10%	ResMed	3%
Stryker	10%	IDEXX Laboratories	3%
Boston Scientific	10%	GE HealthCare	3%
Intuitive Surgical	10%	DexCom	3%
Medtronic	5%	CooperCompanies	2%
EssilorLuxottica	4%	Steris	2%
Alcon	4%	Align Technology	2%
Edwards Lifesciences	4%	Insulet	2%
Becton Dickinson	4%	Hologic	2%
HOYA	4%	13 small holdings	14%

### Currency breakdown

USD	78%	JPY	5%
CHF	8%	DKK	2%
EUR	6%	GBP	2%

### Performance Fund class N1 CHF



### Important legal information

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

Performance in CHF	November	2024	1 year	3 years	5 years	10 years	Inception
MIV Global Medtech Fund N1	5.5%	17.4%	21.6%	-7.6%	11.0%	n.a.	54.9%
Benchmark *	5.1%	18.8%	22.6%	-3.9%	21.9%	n.a.	75.0%
MSCI World Index	6.6%	27.5%	29.5%	22.6%	58.3%	n.a.	88.8%
			12.19-11.20	12.20-11.21	12.21-11.22	12.22-11.23	12.23-11.24
MIV Global Medtech Fund N1			2.9%	16.8%	-18.9%	-6.2%	21.6%
Benchmark *			8.9%	16.4%	-16.7%	-5.9%	22.6%
MSCI World Index			3.7%	24.5%	-8.2%	3.1%	29.5%

\* MSCI World Healthcare Equipment & Supplies

### Company Headlines

At the beginning of November, Donald Trump was elected as the new US president. He has appointed Robert F. Kennedy as Health Secretary. Kennedy has raised eyebrows in the past and during the election with controversial statements on vaccination and the pharmaceutical – but not the medical devices – industry. Generally speaking, medtech is not so much in the focus of politicians as the pharmaceutical industry, as the latter generates a much larger portion of healthcare costs, is regulated more strictly via an approval process and patents and regularly attracts attention with substantial price increases. In contrast to migration and economic policy, health is not a key topic for Donald Trump. During his administration we therefore do not anticipate any major reforms for health policy in general or any negative consequences for the medical device industry in particular. During Trump's first term in office, the medtech industry also showed that it was able to react flexibly to new customs duties.

US-based **Stryker** again beat expectations with its results for the third quarter of 2024, which were published at the end of October. Both Orthopaedics and MedSurg (hospital equipment, endoscopy, surgical instruments) & Neurotechnology produced impressive performances. Organic revenue growth amounted to 11.5%, with increased volumes contributing 10.3 percentage points and higher prices 1.2 percentage points. Management highlighted the high patient volumes, continued strong demand in the area of hospital equipment and the record number of interactive Mako robotic arm installations. Stryker's strong level of innovation has enabled it to steadily improve its market share over the years, thus achieving above-average growth rates. The firm is in an attractive product cycle with numerous launches. The forecast published in January for organic revenue growth of 7.5% to 9.0% was improved to between 9.5% and 10% by October. The growth bandwidth for adjusted earnings per share was increased to between 13% and 14%, which should equal the strong previous year.

**GE Healthcare Technologies**, based in Chicago, Illinois, was spun off as an independent company from General Electric in January 2023. It offers a wide range of medical imaging solutions, patient monitoring systems and pharmaceutical diagnostics. During the reporting month it presented its growth strategy and targets for the three-year period to 2028 at its Investor Day in New York City. CEO Peter Arduini and CFO Jay Saccaro emphasised the significance of innovation and digital solutions, particularly in the field of artificial intelligence (AI) and cloud technologies. The targets include annual organic revenue growth in the mid-single-digit range, considerable margin increases and a rise in earnings in the high single-digit to low double-digit percentage range. The plan is to use the very attractive cash flow for value-adding measures.

## Investments in medical devices

### Investment Strategy

The MIV Global Medtech Fund invests globally in listed medical device companies. The investment process is based on a combined top-down / bottom-up approach. Against the background of the particular macroeconomic environment, the most interesting markets and companies are determined based on an intensive primary analysis. Alongside an attractive valuation, a strong market position, good growth potential, excellent products, sustainable profitability and high-quality management are the decisive parameters for investment. The consideration of sustainability criteria (ESG) is integrated in the research, analysis and investment process. Risks are managed by means of portfolio diversification. The portfolio of the MIV Global Medtech Fund is structured more defensively or cyclically in the best possible anticipation of economic trends, with a view to achieving a higher return than the benchmark and the general market indices.

### Benefits

Owing to demographic trends and the desire for quality of life and mobility, the medical device industry is a long-term growth market. Emerging markets will have a positive impact on the medical device industry's future growth thanks to the state-backed expansion of their healthcare systems. Medical device suppliers' priority is the development of innovative, minimally invasive products. These are beneficial for patients and cost efficient for the healthcare system due to shorter convalescence periods. Most interesting from an investor's perspective are the industry's high growth rates, above-average profitability and oligopolistic market structures with their high entry barriers for new competitors. Even in a demanding environment, significant product innovations continue to offer attractive growth prospects.

### Risks

The MIV Global Medtech Fund invests in equity securities and may therefore be subject to high fluctuations in value. For this reason, a medium-term to long-term investment horizon and corresponding risk tolerance and capacity are required for an investment into this Sub-Fund. As the MIV Global Medtech Fund pursues an active management style, the Sub-Fund's performance can deviate substantially from that of its reference index. The focus on equity securities of global medical device companies potentially exposes the Sub-Fund to additional sector-specific risks and currency risks. The Sub-Fund may, for the purpose of hedging and the efficient management of the portfolio, make use of derivatives, which can lead to additional risks (particularly counter party risk). All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions.

### Sustainability profile - ESG

MIV Asset Management identifies, monitors and mitigates ESG risks that are, or could become, material to the performance of medical technology companies. The approach is based on the following factors:

- **Integration:** The consideration of sustainability criteria (ESG) is integrated into the research, analysis and investment process. The Fund invests in companies with a good ESG profile. The Fund does not invest in companies with a Sustainalytics ESG Risk Rating above 40 (severe) as well as a Sustainalytics Controversy Score above 4 (high).
- **Exclusion:** The Fund excludes investments in companies, that are not compliant with global norms (OECD Guidelines for Multinational Enterprises, UN Guiding Principles for Business and Human Rights, International Labour Organization's Fundamental Principles) as well as investments in controversial industries (particularly conventional and controversial weapons).
- **Sustainable Investments:** A minimum portion of 33% of assets is invested in Sustainable Investments with a social objective (contribution to UN Sustainable Development Goals).
- **Dialogue:** Close and regular contact with the management of actual and potential investments, amongst other, with the goal of improving ESG practices and disclosure at these companies.
- **Ownership rights:** Exercise of MIV Global Medtech Fund's voting rights delegated to the ISS proxy with Sustainability Policy. In case of controversial decisions, MIV Asset Management gets directly involved.

- The MIV Global Medtech Fund is classified as a financial product under **EU SFDR Article 8**
- MIV Asset Management is a signatory to the **UN Principles for Responsible Investment**
- The MIV Global Medtech Fund's investments support **UN Sustainable Development Goals, in particular no. 1, 3, 5, 8 and 10**
- MIV Asset Management works together with the **proxy ISS with Sustainability Policy**
- The MIV Global Medtech Fund has an **above-average MSCI ESG Score (6.5) and MSCI ESG Rating (A)**
- The MIV Global Medtech Fund has an **above-average Sustainalytics ESG profile**

### Glossary

Benchmark	An index, which is used as a reference for the measurement of the performance of the Fund.
Inception	Launch date of the Fund and/or the Fund class.
Management fee	Portfolio manager's fee for the management and the distribution of the Fund.
NAV	Net Asset Value: total Fund assets divided by total number of Fund shares outstanding.
TER	Total Expense Ratio: sum of all fees and costs, which are charged to the Fund on a continuous basis.

## Investments in medical devices

### Information

Website	www.mivglobalmedtech.ch
Legal structure	Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law
Fund class	<b>N1</b> (CHF) accumulation / ISIN: LU1769944791 / Swiss Valor Number: 40341180 / WKN: A2JGMD
Subscription/redemption	On every bank working day in Luxembourg until 3.45 p.m. at net asset value (no calculation of net asset values on bank/stock exchange holidays in Luxembourg and/or the US)
Management fee	1.0% p.a.
Total Expense Ratio (TER) as of 30.6.2024	1.17%
Launch of fund	11 March 2008
Launch of fund class N1	6 March 2018
Close of financial year	30 June
Benchmark	MSCI World Healthcare Equipment & Supplies
Reporting of the Portfolio manager	Monthly, semester and yearly report
Fund price monitoring	www.mivglobalmedtech.ch / www.swissfunddata.ch / www.fundinfo.com Bloomberg: VARMVN1 LX / Reuters: LU1769944791.LUF / Neue Zürcher Zeitung
Portfolio manager	MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, info@mivglobalmedtech.ch Contact: Christoph Gubler, Giuseppe Di Benedetto, Christoph Greter, Phone +41 44 253 64 11
Management company	Vontobel Asset Management S.A., 18, rue Erasme, L-1468 Luxembourg
Representative for Switzerland	Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich
Custodian/Administrator	State Street Bank International GmbH, 49, Avenue J.F. Kennedy, L-1855 Luxembourg
Auditor	Ernst & Young S.A., 35E, Avenue J.F. Kennedy, L-1855 Luxembourg
Minimum subscription	none
Admissions to distribution	Switzerland, Germany, Austria, Liechtenstein, Luxembourg, France, Italy, Spain, United Kingdom, Netherlands, Finland, Norway, Sweden, Singapore (restricted scheme)
Distribution restrictions	USA / US persons

### Important legal information

MIV Global Medtech Fund is a Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law. This document is for information purposes only and nothing contained in this document should constitute a solicitation, or offer, or recommendation, to buy or sell any investment instruments, to effect any transactions, or to conclude any legal act of any kind whatsoever. This document has been produced by MIV Asset Management AG. It is explicitly not the result of a financial analysis and therefore the "Directives on the Independence of Financial Research" of the Swiss Bankers Association is not applicable. Although MIV Asset Management AG believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report. Any companies described in this document may or may not currently represent a position in the portfolio of the MIV Global Medtech Fund. Any projections, forecasts or estimates contained in this document are based on a variety of estimates and assumptions. There can be no assurance that the estimates or assumptions made will prove accurate, and actual results may differ materially.

Subscriptions of shares of the Sub-Fund should in any event be made solely on the basis of the current sales prospectus, the current Key Information Documents (KIDs), the current articles of association and the most recent annual and semi-annual reports of Variopartner SICAV. For more details regarding the potential risks of an investment in Sub-Funds of Variopartner SICAV, please refer to the current sales prospectus. Interested parties may obtain the abovementioned documents free of charge from the portfolio manager: MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, the representative for Switzerland: Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich, the paying agent in Switzerland: Bank Vontobel AG, Gotthardstrasse 43, CH-8022 Zurich, the European facilities agent for Germany, Finland, France, Italy, the Netherlands, Norway, Sweden and Spain: PwC Société coopérative – GFD, 2, rue Gerhard Mercator B.P. 1443, L-1014 Luxembourg, [lu\\_pwc.gfd.facsvs@pwc.com](mailto:lu_pwc.gfd.facsvs@pwc.com), the financial and central agent in France: BNP Paribas S.A., 16, Boulevard des Italiens, F-75009 Paris, the Austrian Facility: Erste Bank der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna, the information agent in Liechtenstein: LLB Fund Services AG, Äulestrasse 80, FL-9490 Vaduz, the paying agents in Italy: Banca Sella Holding S.p.A., Piazza Gaudenzio Sella, 1, I-13900 Biella, Allfunds Bank, S.A.U., Via Bocchetto, 6, I-20123 Milan, the facilities agent for the United Kingdom: Carne Financial Services (UK) LLP, 29-30 Cornhill, London EC3V 3ND, and from the offices of the Fund: Variopartner SICAV, 49, Avenue J.F. Kennedy, L-1855 Luxembourg. They may also be downloaded from the website [www.mivglobalmedtech.com](http://www.mivglobalmedtech.com).

Further information on the distribution of the fund's shares in an official language of the respective distribution country can be found on the corresponding website:

Germany	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-de">https://gfdplatform.pwc.lu/facilities-agent/view/vs-de</a>
Finland	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi</a>
France	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr</a>
Italy	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-it">https://gfdplatform.pwc.lu/facilities-agent/view/vs-it</a>
Netherlands	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl">https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl</a>
Norway	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-no">https://gfdplatform.pwc.lu/facilities-agent/view/vs-no</a>
Sweden	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv">https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv</a>
Spain	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-es">https://gfdplatform.pwc.lu/facilities-agent/view/vs-es</a>

This Sub-Fund is registered with the Financial Conduct Authority (FCA) for public distribution in the United Kingdom.

This Sub-Fund is not available to retail investors in Singapore. It is accepted as restricted scheme by the Monetary Authority of Singapore (MAS) and may only be offered to certain prescribed persons on certain conditions as provided in the "Securities and Futures Act", Chapter 289 of Singapore.

This Sub-Fund is not authorised by the Securities and Futures Commission of Hong Kong. It may only be offered to those investors qualifying as professional investors under the Securities and Futures Ordinance. The contents of this document have not been reviewed by any regulatory authority in Hong Kong.

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

# MIV Global Medtech Fund

Sub-Fund of an investment company with variable capital SICAV



Monthly report November 2024

Marketing document for private and institutional investors

## Facts Fund class N2

Net Asset Value per Fund share EUR	2'870.70
Assets EUR m (all Fund classes)	2'132
Investment level	99%
Liquidity	1%

## Industry breakdown

Ophthalmology	12%
Hospital Equipment	10%
Surgical Instruments	7%
Orthopaedics	7%
Diabetes	7%
In-vitro Diagnostics	7%
Disposable Medical Supplies	6%
Endoscopy	5%
Interventional Cardiology	4%
Other Medical Technology Sectors	34%


## Holdings

Abbott Laboratories	10%	ResMed	3%
Stryker	10%	IDEXX Laboratories	3%
Boston Scientific	10%	GE HealthCare	3%
Intuitive Surgical	10%	DexCom	3%
Medtronic	5%	CooperCompanies	2%
EssilorLuxottica	4%	Steris	2%
Alcon	4%	Align Technology	2%
Edwards Lifesciences	4%	Insulet	2%
Becton Dickinson	4%	Hologic	2%
HOYA	4%	13 small holdings	14%

## Currency breakdown

USD	78%	JPY	5%
CHF	8%	DKK	2%
EUR	6%	GBP	2%

## Performance Fund class N2 EUR



## Important legal information

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

Performance in EUR	November	2024	1 year	3 years	5 years	10 years	Inception
MIV Global Medtech Fund N2	6.4%	17.3%	23.9%	3.4%	31.4%	n.a.	93.8%
Benchmark *	6.1%	18.7%	25.1%	7.6%	44.4%	n.a.	119.0%
MSCI World Index	7.5%	27.4%	32.1%	37.2%	87.4%	n.a.	136.3%
			12.19-11.20	12.20-11.21	12.21-11.22	12.22-11.23	12.23-11.24
MIV Global Medtech Fund N2			4.7%	21.5%	-13.9%	-3.1%	23.9%
Benchmark *			10.8%	21.1%	-11.6%	-2.7%	25.1%
MSCI World Index			5.6%	29.4%	-2.6%	6.6%	32.1%

\* MSCI World Healthcare Equipment & Supplies

## Company Headlines

At the beginning of November, Donald Trump was elected as the new US president. He has appointed Robert F. Kennedy as Health Secretary. Kennedy has raised eyebrows in the past and during the election with controversial statements on vaccination and the pharmaceutical – but not the medical devices – industry. Generally speaking, medtech is not so much in the focus of politicians as the pharmaceutical industry, as the latter generates a much larger portion of healthcare costs, is regulated more strictly via an approval process and patents and regularly attracts attention with substantial price increases. In contrast to migration and economic policy, health is not a key topic for Donald Trump. During his administration we therefore do not anticipate any major reforms for health policy in general or any negative consequences for the medical device industry in particular. During Trump's first term in office, the medtech industry also showed that it was able to react flexibly to new customs duties.

US-based **Stryker** again beat expectations with its results for the third quarter of 2024, which were published at the end of October. Both Orthopaedics and MedSurg (hospital equipment, endoscopy, surgical instruments) & Neurotechnology produced impressive performances. Organic revenue growth amounted to 11.5%, with increased volumes contributing 10.3 percentage points and higher prices 1.2 percentage points. Management highlighted the high patient volumes, continued strong demand in the area of hospital equipment and the record number of interactive Mako robotic arm installations. Stryker's strong level of innovation has enabled it to steadily improve its market share over the years, thus achieving above-average growth rates. The firm is in an attractive product cycle with numerous launches. The forecast published in January for organic revenue growth of 7.5% to 9.0% was improved to between 9.5% and 10% by October. The growth bandwidth for adjusted earnings per share was increased to between 13% and 14%, which should equal the strong previous year.

**GE Healthcare Technologies**, based in Chicago, Illinois, was spun off as an independent company from General Electric in January 2023. It offers a wide range of medical imaging solutions, patient monitoring systems and pharmaceutical diagnostics. During the reporting month it presented its growth strategy and targets for the three-year period to 2028 at its Investor Day in New York City. CEO Peter Arduini and CFO Jay Saccaro emphasised the significance of innovation and digital solutions, particularly in the field of artificial intelligence (AI) and cloud technologies. The targets include annual organic revenue growth in the mid-single-digit range, considerable margin increases and a rise in earnings in the high single-digit to low double-digit percentage range. The plan is to use the very attractive cash flow for value-adding measures.

## Investments in medical devices

### Investment Strategy

The MIV Global Medtech Fund invests globally in listed medical device companies. The investment process is based on a combined top-down / bottom-up approach. Against the background of the particular macroeconomic environment, the most interesting markets and companies are determined based on an intensive primary analysis. Alongside an attractive valuation, a strong market position, good growth potential, excellent products, sustainable profitability and high-quality management are the decisive parameters for investment. The consideration of sustainability criteria (ESG) is integrated in the research, analysis and investment process. Risks are managed by means of portfolio diversification. The portfolio of the MIV Global Medtech Fund is structured more defensively or cyclically in the best possible anticipation of economic trends, with a view to achieving a higher return than the benchmark and the general market indices.

### Benefits

Owing to demographic trends and the desire for quality of life and mobility, the medical device industry is a long-term growth market. Emerging markets will have a positive impact on the medical device industry's future growth thanks to the state-backed expansion of their healthcare systems. Medical device suppliers' priority is the development of innovative, minimally invasive products. These are beneficial for patients and cost efficient for the healthcare system due to shorter convalescence periods. Most interesting from an investor's perspective are the industry's high growth rates, above-average profitability and oligopolistic market structures with their high entry barriers for new competitors. Even in a demanding environment, significant product innovations continue to offer attractive growth prospects.

### Risks

The MIV Global Medtech Fund invests in equity securities and may therefore be subject to high fluctuations in value. For this reason, a medium-term to long-term investment horizon and corresponding risk tolerance and capacity are required for an investment into this Sub-Fund. As the MIV Global Medtech Fund pursues an active management style, the Sub-Fund's performance can deviate substantially from that of its reference index. The focus on equity securities of global medical device companies potentially exposes the Sub-Fund to additional sector-specific risks and currency risks. The Sub-Fund may, for the purpose of hedging and the efficient management of the portfolio, make use of derivatives, which can lead to additional risks (particularly counter party risk). All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions.

### Sustainability profile - ESG

MIV Asset Management identifies, monitors and mitigates ESG risks that are, or could become, material to the performance of medical technology companies. The approach is based on the following factors:

- **Integration:** The consideration of sustainability criteria (ESG) is integrated into the research, analysis and investment process. The Fund invests in companies with a good ESG profile. The Fund does not invest in companies with a Sustainalytics ESG Risk Rating above 40 (severe) as well as a Sustainalytics Controversy Score above 4 (high).
- **Exclusion:** The Fund excludes investments in companies, that are not compliant with global norms (OECD Guidelines for Multinational Enterprises, UN Guiding Principles for Business and Human Rights, International Labour Organization's Fundamental Principles) as well as investments in controversial industries (particularly conventional and controversial weapons).
- **Sustainable Investments:** A minimum portion of 33% of assets is invested in Sustainable Investments with a social objective (contribution to UN Sustainable Development Goals).
- **Dialogue:** Close and regular contact with the management of actual and potential investments, amongst other, with the goal of improving ESG practices and disclosure at these companies.
- **Ownership rights:** Exercise of MIV Global Medtech Fund's voting rights delegated to the ISS proxy with Sustainability Policy. In case of controversial decisions, MIV Asset Management gets directly involved.

- The MIV Global Medtech Fund is classified as a financial product under **EU SFDR Article 8**
- MIV Asset Management is a signatory to the **UN Principles for Responsible Investment**
- The MIV Global Medtech Fund's investments support **UN Sustainable Development Goals, in particular no. 1, 3, 5, 8 and 10**
- MIV Asset Management works together with the **proxy ISS with Sustainability Policy**
- The MIV Global Medtech Fund has an **above-average MSCI ESG Score (6.5) and MSCI ESG Rating (A)**
- The MIV Global Medtech Fund has an **above-average Sustainalytics ESG profile**

### Glossary

Benchmark	An index, which is used as a reference for the measurement of the performance of the Fund.
Inception	Launch date of the Fund and/or the Fund class.
Management fee	Portfolio manager's fee for the management and the distribution of the Fund.
NAV	Net Asset Value: total Fund assets divided by total number of Fund shares outstanding.
TER	Total Expense Ratio: sum of all fees and costs, which are charged to the Fund on a continuous basis.

## Investments in medical devices

### Information

Website	www.mivglobalmedtech.ch
Legal structure	Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law
Fund class	<b>N2</b> (EUR) accumulation / ISIN: LU1769944874 / Swiss Valor Number: 40341212 / WKN: A2JGME
Subscription/redemption	On every bank working day in Luxembourg until 3.45 p.m. at net asset value (no calculation of net asset values on bank/stock exchange holidays in Luxembourg and/or the US)
Management fee	1.0% p.a.
Total Expense Ratio (TER) as of 30.6.2024	1.17%
Launch of fund	11 March 2008
Launch of fund class N2	6 March 2018
Close of financial year	30 June
Benchmark	MSCI World Healthcare Equipment & Supplies
Reporting of the Portfolio manager	Monthly, semester and yearly report
Fund price monitoring	www.mivglobalmedtech.ch / www.swissfunddata.ch / www.fundinfo.com Bloomberg: VARMVN2 LX / Reuters: LU1769944874.LUF / Neue Zürcher Zeitung
Portfolio manager	MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, info@mivglobalmedtech.ch Contact: Christoph Gubler, Giuseppe Di Benedetto, Christoph Greter, Phone +41 44 253 64 11
Management company	Vontobel Asset Management S.A., 18, rue Erasme, L-1468 Luxembourg
Representative for Switzerland	Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich
Custodian/Administrator	State Street Bank International GmbH, 49, Avenue J.F. Kennedy, L-1855 Luxembourg
Auditor	Ernst & Young S.A., 35E, Avenue J.F. Kennedy, L-1855 Luxembourg
Minimum subscription	none
Admissions to distribution	Switzerland, Germany, Austria, Liechtenstein, Luxembourg, France, Italy, Spain, United Kingdom, Netherlands, Finland, Norway, Sweden, Singapore (restricted scheme)
Distribution restrictions	USA / US persons

### Important legal information

MIV Global Medtech Fund is a Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law. This document is for information purposes only and nothing contained in this document should constitute a solicitation, or offer, or recommendation, to buy or sell any investment instruments, to effect any transactions, or to conclude any legal act of any kind whatsoever. This document has been produced by MIV Asset Management AG. It is explicitly not the result of a financial analysis and therefore the "Directives on the Independence of Financial Research" of the Swiss Bankers Association is not applicable. Although MIV Asset Management AG believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report. Any companies described in this document may or may not currently represent a position in the portfolio of the MIV Global Medtech Fund. Any projections, forecasts or estimates contained in this document are based on a variety of estimates and assumptions. There can be no assurance that the estimates or assumptions made will prove accurate, and actual results may differ materially.

Subscriptions of shares of the Sub-Fund should in any event be made solely on the basis of the current sales prospectus, the current Key Information Documents (KIDs), the current articles of association and the most recent annual and semi-annual reports of Variopartner SICAV. For more details regarding the potential risks of an investment in Sub-Funds of Variopartner SICAV, please refer to the current sales prospectus. Interested parties may obtain the abovementioned documents free of charge from the portfolio manager: MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, the representative for Switzerland: Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich, the paying agent in Switzerland: Bank Vontobel AG, Gotthardstrasse 43, CH-8022 Zurich, the European facilities agent for Germany, Finland, France, Italy, the Netherlands, Norway, Sweden and Spain: PwC Société coopérative – GFD, 2, rue Gerhard Mercator B.P. 1443, L-1014 Luxembourg, [lu\\_pwc.gfd.facsvs@pwc.com](mailto:lu_pwc.gfd.facsvs@pwc.com), the financial and central agent in France: BNP Paribas S.A., 16, Boulevard des Italiens, F-75009 Paris, the Austrian Facility: Erste Bank der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna, the information agent in Liechtenstein: LLB Fund Services AG, Äulestrasse 80, FL-9490 Vaduz, the paying agents in Italy: Banca Sella Holding S.p.A., Piazza Gaudenzio Sella, 1, I-13900 Biella, Allfunds Bank, S.A.U., Via Bocchetto, 6, I-20123 Milan, the facilities agent for the United Kingdom: Carne Financial Services (UK) LLP, 29-30 Cornhill, London EC3V 3ND, and from the offices of the Fund: Variopartner SICAV, 49, Avenue J.F. Kennedy, L-1855 Luxembourg. They may also be downloaded from the website [www.mivglobalmedtech.com](http://www.mivglobalmedtech.com).

Further information on the distribution of the fund's shares in an official language of the respective distribution country can be found on the corresponding website:

Germany	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-de">https://gfdplatform.pwc.lu/facilities-agent/view/vs-de</a>
Finland	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi</a>
France	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr</a>
Italy	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-it">https://gfdplatform.pwc.lu/facilities-agent/view/vs-it</a>
Netherlands	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl">https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl</a>
Norway	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-no">https://gfdplatform.pwc.lu/facilities-agent/view/vs-no</a>
Sweden	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv">https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv</a>
Spain	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-es">https://gfdplatform.pwc.lu/facilities-agent/view/vs-es</a>

This Sub-Fund is registered with the Financial Conduct Authority (FCA) for public distribution in the United Kingdom.

This Sub-Fund is not available to retail investors in Singapore. It is accepted as restricted scheme by the Monetary Authority of Singapore (MAS) and may only be offered to certain prescribed persons on certain conditions as provided in the "Securities and Futures Act", Chapter 289 of Singapore.

This Sub-Fund is not authorised by the Securities and Futures Commission of Hong Kong. It may only be offered to those investors qualifying as professional investors under the Securities and Futures Ordinance. The contents of this document have not been reviewed by any regulatory authority in Hong Kong.

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

# MIV Global Medtech Fund

Sub-Fund of an investment company with variable capital SICAV



## Monthly report November 2024

Marketing document for private and institutional investors

### Facts Fund class N3

Net Asset Value per Fund share USD	3'030.87
Assets USD m (all Fund classes)	2'252
Investment level	99%
Liquidity	1%

### Industry breakdown

Ophthalmology	12%
Hospital Equipment	10%
Surgical Instruments	7%
Orthopaedics	7%
Diabetes	7%
In-vitro Diagnostics	7%
Disposable Medical Supplies	6%
Endoscopy	5%
Interventional Cardiology	4%
Other Medical Technology Sectors	34%


### Holdings

Abbott Laboratories	10%	ResMed	3%
Stryker	10%	IDEXX Laboratories	3%
Boston Scientific	10%	GE HealthCare	3%
Intuitive Surgical	10%	DexCom	3%
Medtronic	5%	CooperCompanies	2%
EssilorLuxottica	4%	Steris	2%
Alcon	4%	Align Technology	2%
Edwards Lifesciences	4%	Insulet	2%
Becton Dickinson	4%	Hologic	2%
HOYA	4%	13 small holdings	14%

### Currency breakdown

USD	78%	JPY	5%
CHF	8%	DKK	2%
EUR	6%	GBP	2%

### Performance Fund class N3 USD



### Important legal information

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

### Performance in USD

	November	2024	1 year	3 years	5 years	10 years	Inception
MIV Global Medtech Fund N3	3.5%	12.2%	20.0%	-3.0%	25.9%	148.3%	170.9%
Benchmark *	3.2%	13.5%	21.1%	1.0%	38.3%	181.5%	222.1%
MSCI World Index	4.6%	21.8%	27.8%	28.7%	79.5%	160.8%	172.7%
			12.19-11.20	12.20-11.21	12.21-11.22	12.22-11.23	12.23-11.24
MIV Global Medtech Fund N3			13.6%	14.3%	-21.3%	2.7%	20.0%
Benchmark *			20.2%	13.9%	-19.1%	3.1%	21.1%
MSCI World Index			14.5%	21.8%	-10.9%	13.0%	27.8%

\* MSCI World Healthcare Equipment & Supplies

### Company Headlines

At the beginning of November, Donald Trump was elected as the new US president. He has appointed Robert F. Kennedy as Health Secretary. Kennedy has raised eyebrows in the past and during the election with controversial statements on vaccination and the pharmaceutical – but not the medical devices – industry. Generally speaking, medtech is not so much in the focus of politicians as the pharmaceutical industry, as the latter generates a much larger portion of healthcare costs, is regulated more strictly via an approval process and patents and regularly attracts attention with substantial price increases. In contrast to migration and economic policy, health is not a key topic for Donald Trump. During his administration we therefore do not anticipate any major reforms for health policy in general or any negative consequences for the medical device industry in particular. During Trump's first term in office, the medtech industry also showed that it was able to react flexibly to new customs duties.

US-based **Stryker** again beat expectations with its results for the third quarter of 2024, which were published at the end of October. Both Orthopaedics and MedSurg (hospital equipment, endoscopy, surgical instruments) & Neurotechnology produced impressive performances. Organic revenue growth amounted to 11.5%, with increased volumes contributing 10.3 percentage points and higher prices 1.2 percentage points. Management highlighted the high patient volumes, continued strong demand in the area of hospital equipment and the record number of interactive Mako robotic arm installations. Stryker's strong level of innovation has enabled it to steadily improve its market share over the years, thus achieving above-average growth rates. The firm is in an attractive product cycle with numerous launches. The forecast published in January for organic revenue growth of 7.5% to 9.0% was improved to between 9.5% and 10% by October. The growth bandwidth for adjusted earnings per share was increased to between 13% and 14%, which should equal the strong previous year.

**GE Healthcare Technologies**, based in Chicago, Illinois, was spun off as an independent company from General Electric in January 2023. It offers a wide range of medical imaging solutions, patient monitoring systems and pharmaceutical diagnostics. During the reporting month it presented its growth strategy and targets for the three-year period to 2028 at its Investor Day in New York City. CEO Peter Arduini and CFO Jay Saccaro emphasised the significance of innovation and digital solutions, particularly in the field of artificial intelligence (AI) and cloud technologies. The targets include annual organic revenue growth in the mid-single-digit range, considerable margin increases and a rise in earnings in the high single-digit to low double-digit percentage range. The plan is to use the very attractive cash flow for value-adding measures.



## Investments in medical devices

### Investment Strategy

The MIV Global Medtech Fund invests globally in listed medical device companies. The investment process is based on a combined top-down / bottom-up approach. Against the background of the particular macroeconomic environment, the most interesting markets and companies are determined based on an intensive primary analysis. Alongside an attractive valuation, a strong market position, good growth potential, excellent products, sustainable profitability and high-quality management are the decisive parameters for investment. The consideration of sustainability criteria (ESG) is integrated in the research, analysis and investment process. Risks are managed by means of portfolio diversification. The portfolio of the MIV Global Medtech Fund is structured more defensively or cyclically in the best possible anticipation of economic trends, with a view to achieving a higher return than the benchmark and the general market indices.

### Benefits

Owing to demographic trends and the desire for quality of life and mobility, the medical device industry is a long-term growth market. Emerging markets will have a positive impact on the medical device industry's future growth thanks to the state-backed expansion of their healthcare systems. Medical device suppliers' priority is the development of innovative, minimally invasive products. These are beneficial for patients and cost efficient for the healthcare system due to shorter convalescence periods. Most interesting from an investor's perspective are the industry's high growth rates, above-average profitability and oligopolistic market structures with their high entry barriers for new competitors. Even in a demanding environment, significant product innovations continue to offer attractive growth prospects.

### Risks

The MIV Global Medtech Fund invests in equity securities and may therefore be subject to high fluctuations in value. For this reason, a medium-term to long-term investment horizon and corresponding risk tolerance and capacity are required for an investment into this Sub-Fund. As the MIV Global Medtech Fund pursues an active management style, the Sub-Fund's performance can deviate substantially from that of its reference index. The focus on equity securities of global medical device companies potentially exposes the Sub-Fund to additional sector-specific risks and currency risks. The Sub-Fund may, for the purpose of hedging and the efficient management of the portfolio, make use of derivatives, which can lead to additional risks (particularly counter party risk). All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions.

### Sustainability profile - ESG

MIV Asset Management identifies, monitors and mitigates ESG risks that are, or could become, material to the performance of medical technology companies. The approach is based on the following factors:

- **Integration:** The consideration of sustainability criteria (ESG) is integrated into the research, analysis and investment process. The Fund invests in companies with a good ESG profile. The Fund does not invest in companies with a Sustainalytics ESG Risk Rating above 40 (severe) as well as a Sustainalytics Controversy Score above 4 (high).
- **Exclusion:** The Fund excludes investments in companies, that are not compliant with global norms (OECD Guidelines for Multinational Enterprises, UN Guiding Principles for Business and Human Rights, International Labour Organization's Fundamental Principles) as well as investments in controversial industries (particularly conventional and controversial weapons).
- **Sustainable Investments:** A minimum portion of 33% of assets is invested in Sustainable Investments with a social objective (contribution to UN Sustainable Development Goals).
- **Dialogue:** Close and regular contact with the management of actual and potential investments, amongst other, with the goal of improving ESG practices and disclosure at these companies.
- **Ownership rights:** Exercise of MIV Global Medtech Fund's voting rights delegated to the ISS proxy with Sustainability Policy. In case of controversial decisions, MIV Asset Management gets directly involved.

- The MIV Global Medtech Fund is classified as a financial product under **EU SFDR Article 8**
- MIV Asset Management is a signatory to the **UN Principles for Responsible Investment**
- The MIV Global Medtech Fund's investments support **UN Sustainable Development Goals, in particular no. 1, 3, 5, 8 and 10**
- MIV Asset Management works together with the **proxy ISS with Sustainability Policy**
- The MIV Global Medtech Fund has an **above-average MSCI ESG Score (6.5) and MSCI ESG Rating (A)**
- The MIV Global Medtech Fund has an **above-average Sustainalytics ESG profile**

### Glossary

Benchmark	An index, which is used as a reference for the measurement of the performance of the Fund.
Inception	Launch date of the Fund and/or the Fund class.
Management fee	Portfolio manager's fee for the management and the distribution of the Fund.
NAV	Net Asset Value: total Fund assets divided by total number of Fund shares outstanding.
TER	Total Expense Ratio: sum of all fees and costs, which are charged to the Fund on a continuous basis.

## Investments in medical devices

### Information

Website	www.mivglobalmedtech.ch
Legal structure	Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law
Fund class	<b>N3</b> (USD) accumulation / ISIN: LU1050446076 / Swiss Valor Number: 24064488 / Sedol: BLDYW10
Subscription/redemption	On every bank working day in Luxembourg until 3.45 p.m. at net asset value (no calculation of net asset values on bank/stock exchange holidays in Luxembourg and/or the US)
Management fee	1.0% p.a.
Total Expense Ratio (TER) as of 30.6.2024	1.17%
Launch of fund	11 March 2008
Launch of fund class N3	3 April 2014
Close of financial year	30 June
Benchmark	MSCI World Healthcare Equipment & Supplies
Reporting of the Portfolio manager	Monthly, semester and yearly report
Fund price monitoring	www.mivglobalmedtech.ch / www.swissfunddata.ch / www.fundinfo.com Bloomberg: VARMVN3 LX / Reuters: LU1050446076.LUF / Neue Zürcher Zeitung
Portfolio manager	MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, info@mivglobalmedtech.ch Contact: Christoph Gubler, Giuseppe Di Benedetto, Christoph Greter, Phone +41 44 253 64 11
Management company	Vontobel Asset Management S.A., 18, rue Erasme, L-1468 Luxembourg
Representative for Switzerland	Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich
Custodian/Administrator	State Street Bank International GmbH, 49, Avenue J.F. Kennedy, L-1855 Luxembourg
Auditor	Ernst & Young S.A., 35E, Avenue J.F. Kennedy, L-1855 Luxembourg
Minimum subscription	none
Admissions to distribution	Switzerland, Germany, Austria, Liechtenstein, Luxembourg, France, Italy, Spain, United Kingdom, Netherlands, Finland, Norway, Sweden, Singapore (restricted scheme)
Distribution restrictions	USA / US persons

### Important legal information

MIV Global Medtech Fund is a Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law. This document is for information purposes only and nothing contained in this document should constitute a solicitation, or offer, or recommendation, to buy or sell any investment instruments, to effect any transactions, or to conclude any legal act of any kind whatsoever. This document has been produced by MIV Asset Management AG. It is explicitly not the result of a financial analysis and therefore the "Directives on the Independence of Financial Research" of the Swiss Bankers Association is not applicable. Although MIV Asset Management AG believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report. Any companies described in this document may or may not currently represent a position in the portfolio of the MIV Global Medtech Fund. Any projections, forecasts or estimates contained in this document are based on a variety of estimates and assumptions. There can be no assurance that the estimates or assumptions made will prove accurate, and actual results may differ materially.

Subscriptions of shares of the Sub-Fund should in any event be made solely on the basis of the current sales prospectus, the current Key Information Documents (KIDs), the current articles of association and the most recent annual and semi-annual reports of Variopartner SICAV. For more details regarding the potential risks of an investment in Sub-Funds of Variopartner SICAV, please refer to the current sales prospectus. Interested parties may obtain the abovementioned documents free of charge from the portfolio manager: MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, the representative for Switzerland: Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich, the paying agent in Switzerland: Bank Vontobel AG, Gotthardstrasse 43, CH-8022 Zurich, the European facilities agent for Germany, Finland, France, Italy, the Netherlands, Norway, Sweden and Spain: PwC Société coopérative – GFD, 2, rue Gerhard Mercator B.P. 1443, L-1014 Luxembourg, [lu\\_pwc.gfd.facsvs@pwc.com](mailto:lu_pwc.gfd.facsvs@pwc.com), the financial and central agent in France: BNP Paribas S.A., 16, Boulevard des Italiens, F-75009 Paris, the Austrian Facility: Erste Bank der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna, the information agent in Liechtenstein: LLB Fund Services AG, Äulestrasse 80, FL-9490 Vaduz, the paying agents in Italy: Banca Sella Holding S.p.A., Piazza Gaudenzio Sella, 1, I-13900 Biella, Allfunds Bank, S.A.U., Via Bocchetto, 6, I-20123 Milan, the facilities agent for the United Kingdom: Carne Financial Services (UK) LLP, 29-30 Cornhill, London EC3V 3ND, and from the offices of the Fund: Variopartner SICAV, 49, Avenue J.F. Kennedy, L-1855 Luxembourg. They may also be downloaded from the website [www.mivglobalmedtech.com](http://www.mivglobalmedtech.com).

Further information on the distribution of the fund's shares in an official language of the respective distribution country can be found on the corresponding website:

Germany	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-de">https://gfdplatform.pwc.lu/facilities-agent/view/vs-de</a>
Finland	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi</a>
France	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr</a>
Italy	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-it">https://gfdplatform.pwc.lu/facilities-agent/view/vs-it</a>
Netherlands	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl">https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl</a>
Norway	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-no">https://gfdplatform.pwc.lu/facilities-agent/view/vs-no</a>
Sweden	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv">https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv</a>
Spain	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-es">https://gfdplatform.pwc.lu/facilities-agent/view/vs-es</a>

This Sub-Fund is registered with the Financial Conduct Authority (FCA) for public distribution in the United Kingdom.

This Sub-Fund is not available to retail investors in Singapore. It is accepted as restricted scheme by the Monetary Authority of Singapore (MAS) and may only be offered to certain prescribed persons on certain conditions as provided in the "Securities and Futures Act", Chapter 289 of Singapore.

This Sub-Fund is not authorised by the Securities and Futures Commission of Hong Kong. It may only be offered to those investors qualifying as professional investors under the Securities and Futures Ordinance. The contents of this document have not been reviewed by any regulatory authority in Hong Kong.

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

# MIV Global Medtech Fund

Sub-Fund of an investment company with variable capital SICAV



## Monthly report November 2024

Marketing document for private and institutional investors

### Facts Fund class P1

Net Asset Value per Fund share CHF	2'495.55
Assets CHF m (all Fund classes)	1'984
Investment level	99%
Liquidity	1%

### Industry breakdown

Ophthalmology	12%
Hospital Equipment	10%
Surgical Instruments	7%
Orthopaedics	7%
Diabetes	7%
In-vitro Diagnostics	7%
Disposable Medical Supplies	6%
Endoscopy	5%
Interventional Cardiology	4%
Other Medical Technology Sectors	34%


### Holdings

Abbott Laboratories	10%	ResMed	3%
Stryker	10%	IDEXX Laboratories	3%
Boston Scientific	10%	GE HealthCare	3%
Intuitive Surgical	10%	DexCom	3%
Medtronic	5%	CooperCompanies	2%
EssilorLuxottica	4%	Steris	2%
Alcon	4%	Align Technology	2%
Edwards Lifesciences	4%	Insulet	2%
Becton Dickinson	4%	Hologic	2%
HOYA	4%	13 small holdings	14%

### Currency breakdown

USD	78%	JPY	5%
CHF	8%	DKK	2%
EUR	6%	GBP	2%

### Performance Fund class P1 CHF



### Important legal information

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

### Performance in CHF

	November	2024	1 year	3 years	5 years	10 years	Inception
MIV Global Medtech Fund P1	5.5%	17.0%	21.1%	-8.7%	8.8%	118.1%	310.0%
Benchmark *	5.1%	18.8%	22.6%	-3.9%	21.9%	157.4%	309.6%
MSCI World Index	6.6%	27.5%	29.5%	22.6%	58.3%	138.4%	219.2%
			12.19-11.20	12.20-11.21	12.21-11.22	12.22-11.23	12.23-11.24
MIV Global Medtech Fund P1			2.5%	16.4%	-19.3%	-6.6%	21.1%
Benchmark *			8.9%	16.4%	-16.7%	-5.9%	22.6%
MSCI World Index			3.7%	24.5%	-8.2%	3.1%	29.5%

\* MSCI World Healthcare Equipment & Supplies

### Company Headlines

At the beginning of November, Donald Trump was elected as the new US president. He has appointed Robert F. Kennedy as Health Secretary. Kennedy has raised eyebrows in the past and during the election with controversial statements on vaccination and the pharmaceutical – but not the medical devices – industry. Generally speaking, medtech is not so much in the focus of politicians as the pharmaceutical industry, as the latter generates a much larger portion of healthcare costs, is regulated more strictly via an approval process and patents and regularly attracts attention with substantial price increases. In contrast to migration and economic policy, health is not a key topic for Donald Trump. During his administration we therefore do not anticipate any major reforms for health policy in general or any negative consequences for the medical device industry in particular. During Trump's first term in office, the medtech industry also showed that it was able to react flexibly to new customs duties.

US-based **Stryker** again beat expectations with its results for the third quarter of 2024, which were published at the end of October. Both Orthopaedics and MedSurg (hospital equipment, endoscopy, surgical instruments) & Neurotechnology produced impressive performances. Organic revenue growth amounted to 11.5%, with increased volumes contributing 10.3 percentage points and higher prices 1.2 percentage points. Management highlighted the high patient volumes, continued strong demand in the area of hospital equipment and the record number of interactive Mako robotic arm installations. Stryker's strong level of innovation has enabled it to steadily improve its market share over the years, thus achieving above-average growth rates. The firm is in an attractive product cycle with numerous launches. The forecast published in January for organic revenue growth of 7.5% to 9.0% was improved to between 9.5% and 10% by October. The growth bandwidth for adjusted earnings per share was increased to between 13% and 14%, which should equal the strong previous year.

**GE Healthcare Technologies**, based in Chicago, Illinois, was spun off as an independent company from General Electric in January 2023. It offers a wide range of medical imaging solutions, patient monitoring systems and pharmaceutical diagnostics. During the reporting month it presented its growth strategy and targets for the three-year period to 2028 at its Investor Day in New York City. CEO Peter Arduini and CFO Jay Saccaro emphasised the significance of innovation and digital solutions, particularly in the field of artificial intelligence (AI) and cloud technologies. The targets include annual organic revenue growth in the mid-single-digit range, considerable margin increases and a rise in earnings in the high single-digit to low double-digit percentage range. The plan is to use the very attractive cash flow for value-adding measures.

## Investments in medical devices

### Investment Strategy

The MIV Global Medtech Fund invests globally in listed medical device companies. The investment process is based on a combined top-down / bottom-up approach. Against the background of the particular macroeconomic environment, the most interesting markets and companies are determined based on an intensive primary analysis. Alongside an attractive valuation, a strong market position, good growth potential, excellent products, sustainable profitability and high-quality management are the decisive parameters for investment. The consideration of sustainability criteria (ESG) is integrated in the research, analysis and investment process. Risks are managed by means of portfolio diversification. The portfolio of the MIV Global Medtech Fund is structured more defensively or cyclically in the best possible anticipation of economic trends, with a view to achieving a higher return than the benchmark and the general market indices.

### Benefits

Owing to demographic trends and the desire for quality of life and mobility, the medical device industry is a long-term growth market. Emerging markets will have a positive impact on the medical device industry's future growth thanks to the state-backed expansion of their healthcare systems. Medical device suppliers' priority is the development of innovative, minimally invasive products. These are beneficial for patients and cost efficient for the healthcare system due to shorter convalescence periods. Most interesting from an investor's perspective are the industry's high growth rates, above-average profitability and oligopolistic market structures with their high entry barriers for new competitors. Even in a demanding environment, significant product innovations continue to offer attractive growth prospects.

### Risks

The MIV Global Medtech Fund invests in equity securities and may therefore be subject to high fluctuations in value. For this reason, a medium-term to long-term investment horizon and corresponding risk tolerance and capacity are required for an investment into this Sub-Fund. As the MIV Global Medtech Fund pursues an active management style, the Sub-Fund's performance can deviate substantially from that of its reference index. The focus on equity securities of global medical device companies potentially exposes the Sub-Fund to additional sector-specific risks and currency risks. The Sub-Fund may, for the purpose of hedging and the efficient management of the portfolio, make use of derivatives, which can lead to additional risks (particularly counter party risk). All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions.

### Sustainability profile - ESG

MIV Asset Management identifies, monitors and mitigates ESG risks that are, or could become, material to the performance of medical technology companies. The approach is based on the following factors:

- **Integration:** The consideration of sustainability criteria (ESG) is integrated into the research, analysis and investment process. The Fund invests in companies with a good ESG profile. The Fund does not invest in companies with a Sustainalytics ESG Risk Rating above 40 (severe) as well as a Sustainalytics Controversy Score above 4 (high).
- **Exclusion:** The Fund excludes investments in companies, that are not compliant with global norms (OECD Guidelines for Multinational Enterprises, UN Guiding Principles for Business and Human Rights, International Labour Organization's Fundamental Principles) as well as investments in controversial industries (particularly conventional and controversial weapons).
- **Sustainable Investments:** A minimum portion of 33% of assets is invested in Sustainable Investments with a social objective (contribution to UN Sustainable Development Goals).
- **Dialogue:** Close and regular contact with the management of actual and potential investments, amongst other, with the goal of improving ESG practices and disclosure at these companies.
- **Ownership rights:** Exercise of MIV Global Medtech Fund's voting rights delegated to the ISS proxy with Sustainability Policy. In case of controversial decisions, MIV Asset Management gets directly involved.

- The MIV Global Medtech Fund is classified as a financial product under **EU SFDR Article 8**
- MIV Asset Management is a signatory to the **UN Principles for Responsible Investment**
- The MIV Global Medtech Fund's investments support **UN Sustainable Development Goals, in particular no. 1, 3, 5, 8 and 10**
- MIV Asset Management works together with the **proxy ISS with Sustainability Policy**
- The MIV Global Medtech Fund has an **above-average MSCI ESG Score (6.5) and MSCI ESG Rating (A)**
- The MIV Global Medtech Fund has an **above-average Sustainalytics ESG profile**

### Glossary

Benchmark	An index, which is used as a reference for the measurement of the performance of the Fund.
Inception	Launch date of the Fund and/or the Fund class.
Management fee	Portfolio manager's fee for the management and the distribution of the Fund.
NAV	Net Asset Value: total Fund assets divided by total number of Fund shares outstanding.
TER	Total Expense Ratio: sum of all fees and costs, which are charged to the Fund on a continuous basis.

## Investments in medical devices

### Information

Website	www.mivglobalmedtech.com
Legal structure	Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law
Fund class	<b>P1</b> (CHF) accumulation / ISIN: LU0329630999 / Swiss Valor Number: 3535010 / WKN: A0NBNA
Subscription/redemption	On every bank working day in Luxembourg until 3.45 p.m. at net asset value (no calculation of net asset values on bank/stock exchange holidays in Luxembourg and/or the US)
Management fee	1.4% p.a.
Total Expense Ratio (TER) as of 30.6.2024	1.57%
Launch of fund	11 March 2008
Close of financial year	30 June
Benchmark	MSCI World Healthcare Equipment & Supplies
Reporting of the Portfolio manager	Monthly, semester and yearly report
Fund price monitoring	www.mivglobalmedtech.com / www.swissfunddata.ch / www.fundinfo.com Bloomberg: VARMVP1 LX / Reuters: LU0329630999.LUF / Neue Zürcher Zeitung
Portfolio manager	MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, info@mivglobalmedtech.ch Contact: Christoph Gubler, Giuseppe Di Benedetto, Christoph Gretler, Phone +41 44 253 64 11
Management company	Vontobel Asset Management S.A., 18, rue Erasme, L-1468 Luxembourg
Representative for Switzerland	Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich
Custodian/Administrator	State Street Bank International GmbH, 49, Avenue J.F. Kennedy, L-1855 Luxembourg
Auditor	Ernst & Young S.A., 35E, Avenue J.F. Kennedy, L-1855 Luxembourg
Minimum subscription	none
Admissions to distribution	Switzerland, Germany, Austria, Liechtenstein, Luxembourg, France, Italy, Spain, Finland, Norway, Sweden, Singapore (restricted scheme)
Distribution restrictions	USA / US persons

### Important legal information

MIV Global Medtech Fund is a Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law. This document is for information purposes only and nothing contained in this document should constitute a solicitation, or offer, or recommendation, to buy or sell any investment instruments, to effect any transactions, or to conclude any legal act of any kind whatsoever. This document has been produced by MIV Asset Management AG. It is explicitly not the result of a financial analysis and therefore the "Directives on the Independence of Financial Research" of the Swiss Bankers Association is not applicable. Although MIV Asset Management AG believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report. Any companies described in this document may or may not currently represent a position in the portfolio of the MIV Global Medtech Fund. Any projections, forecasts or estimates contained in this document are based on a variety of estimates and assumptions. There can be no assurance that the estimates or assumptions made will prove accurate, and actual results may differ materially.

Subscriptions of shares of the Sub-Fund should in any event be made solely on the basis of the current sales prospectus, the current Key Information Documents (KIDs), the current articles of association and the most recent annual and semi-annual reports of Variopartner SICAV. For more details regarding the potential risks of an investment in Sub-Funds of Variopartner SICAV, please refer to the current sales prospectus. Interested parties may obtain the abovementioned documents free of charge from the portfolio manager: MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, the representative for Switzerland: Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich, the paying agent in Switzerland: Bank Vontobel AG, Gotthardstrasse 43, CH-8022 Zurich, the European facilities agent for Germany, Finland, France, Italy, the Netherlands, Norway, Sweden and Spain: PwC Société coopérative – GFD, 2, rue Gerhard Mercator B.P. 1443, L-1014 Luxembourg, [lu\\_pwc.gfd.facsvs@pwc.com](mailto:lu_pwc.gfd.facsvs@pwc.com), the financial and central agent in France: BNP Paribas S.A., 16, Boulevard des Italiens, F-75009 Paris, the Austrian Facility: Erste Bank der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna, the information agent in Liechtenstein: LLB Fund Services AG, Äulestrasse 80, FL-9490 Vaduz, the paying agents in Italy: Banca Sella Holding S.p.A., Piazza Gaudenzio Sella, 1, I-13900 Biella, Allfunds Bank, S.A.U., Via Bocchetto, 6, I-20123 Milan, and from the offices of the Fund: Variopartner SICAV, 49, Avenue J.F. Kennedy, L-1855 Luxembourg. They may also be downloaded from the website [www.mivglobalmedtech.com](http://www.mivglobalmedtech.com).

Further information on the distribution of the fund's shares in an official language of the respective distribution country can be found on the corresponding website:

Germany	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-de">https://gfdplatform.pwc.lu/facilities-agent/view/vs-de</a>
Finland	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi</a>
France	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr</a>
Italy	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-it">https://gfdplatform.pwc.lu/facilities-agent/view/vs-it</a>
Netherlands	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl">https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl</a>
Norway	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-no">https://gfdplatform.pwc.lu/facilities-agent/view/vs-no</a>
Sweden	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv">https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv</a>
Spain	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-es">https://gfdplatform.pwc.lu/facilities-agent/view/vs-es</a>

This Sub-Fund is not available to retail investors in Singapore. It is accepted as restricted scheme by the Monetary Authority of Singapore (MAS) and may only be offered to certain prescribed persons on certain conditions as provided in the "Securities and Futures Act", Chapter 289 of Singapore.

This Sub-Fund is not authorised by the Securities and Futures Commission of Hong Kong. It may only be offered to those investors qualifying as professional investors under the Securities and Futures Ordinance. The contents of this document have not been reviewed by any regulatory authority in Hong Kong.

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

# MIV Global Medtech Fund

Sub-Fund of an investment company with variable capital SICAV



## Monthly report November 2024

Marketing document for private and institutional investors

### Facts Fund class P2

Net Asset Value per Fund share EUR	2'682.21
Assets EUR m (all Fund classes)	2'132
Investment level	99%
Liquidity	1%

### Industry breakdown

Ophthalmology	12%
Hospital Equipment	10%
Surgical Instruments	7%
Orthopaedics	7%
Diabetes	7%
In-vitro Diagnostics	7%
Disposable Medical Supplies	6%
Endoscopy	5%
Interventional Cardiology	4%
Other Medical Technology Sectors	34%


### Holdings

Abbott Laboratories	10%	ResMed	3%
Stryker	10%	IDEXX Laboratories	3%
Boston Scientific	10%	GE HealthCare	3%
Intuitive Surgical	10%	DexCom	3%
Medtronic	5%	CooperCompanies	2%
EssilorLuxottica	4%	Steris	2%
Alcon	4%	Align Technology	2%
Edwards Lifesciences	4%	Insulet	2%
Becton Dickinson	4%	Hologic	2%
HOYA	4%	13 small holdings	14%

### Currency breakdown

USD	78%	JPY	5%
CHF	8%	DKK	2%
EUR	6%	GBP	2%

### Performance Fund class P2 EUR



### Important legal information

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

### Performance in EUR

	November	2024	1 year	3 years	5 years	10 years	Inception
MIV Global Medtech Fund P2	6.4%	16.9%	23.4%	2.2%	28.8%	181.6%	542.1%
Benchmark *	6.1%	18.7%	25.1%	7.6%	44.4%	232.3%	571.2%
MSCI World Index	7.5%	27.4%	32.1%	37.2%	87.4%	207.8%	475.3%
			12.19-11.20	12.20-11.21	12.21-11.22	12.22-11.23	12.23-11.24
MIV Global Medtech Fund P2			4.2%	21.0%	-14.3%	-3.4%	23.4%
Benchmark *			10.8%	21.1%	-11.6%	-2.7%	25.1%
MSCI World Index			5.6%	29.4%	-2.6%	6.6%	32.1%

\* MSCI World Healthcare Equipment & Supplies

### Company Headlines

At the beginning of November, Donald Trump was elected as the new US president. He has appointed Robert F. Kennedy as Health Secretary. Kennedy has raised eyebrows in the past and during the election with controversial statements on vaccination and the pharmaceutical – but not the medical devices – industry. Generally speaking, medtech is not so much in the focus of politicians as the pharmaceutical industry, as the latter generates a much larger portion of healthcare costs, is regulated more strictly via an approval process and patents and regularly attracts attention with substantial price increases. In contrast to migration and economic policy, health is not a key topic for Donald Trump. During his administration we therefore do not anticipate any major reforms for health policy in general or any negative consequences for the medical device industry in particular. During Trump's first term in office, the medtech industry also showed that it was able to react flexibly to new customs duties.

US-based **Stryker** again beat expectations with its results for the third quarter of 2024, which were published at the end of October. Both Orthopaedics and MedSurg (hospital equipment, endoscopy, surgical instruments) & Neurotechnology produced impressive performances. Organic revenue growth amounted to 11.5%, with increased volumes contributing 10.3 percentage points and higher prices 1.2 percentage points. Management highlighted the high patient volumes, continued strong demand in the area of hospital equipment and the record number of interactive Mako robotic arm installations. Stryker's strong level of innovation has enabled it to steadily improve its market share over the years, thus achieving above-average growth rates. The firm is in an attractive product cycle with numerous launches. The forecast published in January for organic revenue growth of 7.5% to 9.0% was improved to between 9.5% and 10% by October. The growth bandwidth for adjusted earnings per share was increased to between 13% and 14%, which should equal the strong previous year.

**GE Healthcare Technologies**, based in Chicago, Illinois, was spun off as an independent company from General Electric in January 2023. It offers a wide range of medical imaging solutions, patient monitoring systems and pharmaceutical diagnostics. During the reporting month it presented its growth strategy and targets for the three-year period to 2028 at its Investor Day in New York City. CEO Peter Arduini and CFO Jay Saccaro emphasised the significance of innovation and digital solutions, particularly in the field of artificial intelligence (AI) and cloud technologies. The targets include annual organic revenue growth in the mid-single-digit range, considerable margin increases and a rise in earnings in the high single-digit to low double-digit percentage range. The plan is to use the very attractive cash flow for value-adding measures.

## Investments in medical devices

### Investment Strategy

The MIV Global Medtech Fund invests globally in listed medical device companies. The investment process is based on a combined top-down / bottom-up approach. Against the background of the particular macroeconomic environment, the most interesting markets and companies are determined based on an intensive primary analysis. Alongside an attractive valuation, a strong market position, good growth potential, excellent products, sustainable profitability and high-quality management are the decisive parameters for investment. The consideration of sustainability criteria (ESG) is integrated in the research, analysis and investment process. Risks are managed by means of portfolio diversification. The portfolio of the MIV Global Medtech Fund is structured more defensively or cyclically in the best possible anticipation of economic trends, with a view to achieving a higher return than the benchmark and the general market indices.

### Benefits

Owing to demographic trends and the desire for quality of life and mobility, the medical device industry is a long-term growth market. Emerging markets will have a positive impact on the medical device industry's future growth thanks to the state-backed expansion of their healthcare systems. Medical device suppliers' priority is the development of innovative, minimally invasive products. These are beneficial for patients and cost efficient for the healthcare system due to shorter convalescence periods. Most interesting from an investor's perspective are the industry's high growth rates, above-average profitability and oligopolistic market structures with their high entry barriers for new competitors. Even in a demanding environment, significant product innovations continue to offer attractive growth prospects.

### Risks

The MIV Global Medtech Fund invests in equity securities and may therefore be subject to high fluctuations in value. For this reason, a medium-term to long-term investment horizon and corresponding risk tolerance and capacity are required for an investment into this Sub-Fund. As the MIV Global Medtech Fund pursues an active management style, the Sub-Fund's performance can deviate substantially from that of its reference index. The focus on equity securities of global medical device companies potentially exposes the Sub-Fund to additional sector-specific risks and currency risks. The Sub-Fund may, for the purpose of hedging and the efficient management of the portfolio, make use of derivatives, which can lead to additional risks (particularly counter party risk). All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions.

### Sustainability profile - ESG

MIV Asset Management identifies, monitors and mitigates ESG risks that are, or could become, material to the performance of medical technology companies. The approach is based on the following factors:

- **Integration:** The consideration of sustainability criteria (ESG) is integrated into the research, analysis and investment process. The Fund invests in companies with a good ESG profile. The Fund does not invest in companies with a Sustainalytics ESG Risk Rating above 40 (severe) as well as a Sustainalytics Controversy Score above 4 (high).
- **Exclusion:** The Fund excludes investments in companies, that are not compliant with global norms (OECD Guidelines for Multinational Enterprises, UN Guiding Principles for Business and Human Rights, International Labour Organization's Fundamental Principles) as well as investments in controversial industries (particularly conventional and controversial weapons).
- **Sustainable Investments:** A minimum portion of 33% of assets is invested in Sustainable Investments with a social objective (contribution to UN Sustainable Development Goals).
- **Dialogue:** Close and regular contact with the management of actual and potential investments, amongst other, with the goal of improving ESG practices and disclosure at these companies.
- **Ownership rights:** Exercise of MIV Global Medtech Fund's voting rights delegated to the ISS proxy with Sustainability Policy. In case of controversial decisions, MIV Asset Management gets directly involved.

- The MIV Global Medtech Fund is classified as a financial product under **EU SFDR Article 8**
- MIV Asset Management is a signatory to the **UN Principles for Responsible Investment**
- The MIV Global Medtech Fund's investments support **UN Sustainable Development Goals, in particular no. 1, 3, 5, 8 and 10**
- MIV Asset Management works together with the **proxy ISS with Sustainability Policy**
- The MIV Global Medtech Fund has an **above-average MSCI ESG Score (6.5) and MSCI ESG Rating (A)**
- The MIV Global Medtech Fund has an **above-average Sustainalytics ESG profile**

### Glossary

Benchmark	An index, which is used as a reference for the measurement of the performance of the Fund.
Inception	Launch date of the Fund and/or the Fund class.
Management fee	Portfolio manager's fee for the management and the distribution of the Fund.
NAV	Net Asset Value: total Fund assets divided by total number of Fund shares outstanding.
TER	Total Expense Ratio: sum of all fees and costs, which are charged to the Fund on a continuous basis.

## Investments in medical devices

### Information

Website	<a href="http://www.mivglobalmedtech.com">www.mivglobalmedtech.com</a>
Legal structure	Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law
Fund class	<b>P2</b> (EUR) accumulation / ISIN: LU0329630130 / Swiss Valor Number: 3535023 / WKN: A0NETR
Subscription/redemption	On every bank working day in Luxembourg until 3.45 p.m. at net asset value (no calculation of net asset values on bank/stock exchange holidays in Luxembourg and/or the US)
Management fee	1.4% p.a.
Total Expense Ratio (TER) as of 30.6.2024	1.57%
Launch of fund	11 March 2008
Launch of fund class P2	13 January 2010
Close of financial year	30 June
Benchmark	MSCI World Healthcare Equipment & Supplies
Reporting of the Portfolio manager	Monthly, semester and yearly report
Fund price monitoring	<a href="http://www.mivglobalmedtech.com">www.mivglobalmedtech.com</a> / <a href="http://www.swissfunddata.ch">www.swissfunddata.ch</a> / <a href="http://www.fundinfo.com">www.fundinfo.com</a> Bloomberg: VARMVP2 LX / Reuters: LU0329630130.LUF / Neue Zürcher Zeitung
Portfolio manager	MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, <a href="mailto:info@mivglobalmedtech.ch">info@mivglobalmedtech.ch</a> Contact: Christoph Gubler, Giuseppe Di Benedetto, Christoph Greter, Phone +41 44 253 64 11
Management company	Vontobel Asset Management S.A., 18, rue Erasme, L-1468 Luxembourg
Representative for Switzerland	Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich
Custodian/Administrator	State Street Bank International GmbH, 49, Avenue J.F. Kennedy, L-1855 Luxembourg
Auditor	Ernst & Young S.A., 35E, Avenue J.F. Kennedy, L-1855 Luxembourg
Minimum subscription	none
Admissions to distribution	Switzerland, Germany, Austria, Liechtenstein, Luxembourg, France, Italy, Spain, Finland, Norway, Sweden, Singapore (restricted scheme)
Distribution restrictions	USA / US persons

### Important legal information

MIV Global Medtech Fund is a Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law. This document is for information purposes only and nothing contained in this document should constitute a solicitation, or offer, or recommendation, to buy or sell any investment instruments, to effect any transactions, or to conclude any legal act of any kind whatsoever. This document has been produced by MIV Asset Management AG. It is explicitly not the result of a financial analysis and therefore the "Directives on the Independence of Financial Research" of the Swiss Bankers Association is not applicable. Although MIV Asset Management AG believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report. Any companies described in this document may or may not currently represent a position in the portfolio of the MIV Global Medtech Fund. Any projections, forecasts or estimates contained in this document are based on a variety of estimates and assumptions. There can be no assurance that the estimates or assumptions made will prove accurate, and actual results may differ materially.

Subscriptions of shares of the Sub-Fund should in any event be made solely on the basis of the current sales prospectus, the current Key Information Documents (KIDs), the current articles of association and the most recent annual and semi-annual reports of Variopartner SICAV. For more details regarding the potential risks of an investment in Sub-Funds of Variopartner SICAV, please refer to the current sales prospectus. Interested parties may obtain the abovementioned documents free of charge from the portfolio manager: MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, the representative for Switzerland: Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich, the paying agent in Switzerland: Bank Vontobel AG, Gotthardstrasse 43, CH-8022 Zurich, the European facilities agent for Germany, Finland, France, Italy, the Netherlands, Norway, Sweden and Spain: PwC Société coopérative – GFD, 2, rue Gerhard Mercator B.P. 1443, L-1014 Luxembourg, [lu\\_pwc.gfd.facsvs@pwc.com](mailto:lu_pwc.gfd.facsvs@pwc.com), the financial and central agent in France: BNP Paribas S.A., 16, Boulevard des Italiens, F-75009 Paris, the Austrian Facility: Erste Bank der österreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna, the information agent in Liechtenstein: LLB Fund Services AG, Äulestrasse 80, FL-9490 Vaduz, the paying agents in Italy: Banca Sella Holding S.p.A., Piazza Gaudenzio Sella, 1, I-13900 Biella, Allfunds Bank, S.A.U., Via Bocchetto, 6, I-20123 Milan, and from the offices of the Fund: Variopartner SICAV, 49, Avenue J.F. Kennedy, L-1855 Luxembourg. They may also be downloaded from the website [www.mivglobalmedtech.com](http://www.mivglobalmedtech.com).

Further information on the distribution of the fund's shares in an official language of the respective distribution country can be found on the corresponding website:

Germany	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-de">https://gfdplatform.pwc.lu/facilities-agent/view/vs-de</a>
Finland	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi</a>
France	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr</a>
Italy	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-it">https://gfdplatform.pwc.lu/facilities-agent/view/vs-it</a>
Netherlands	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl">https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl</a>
Norway	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-no">https://gfdplatform.pwc.lu/facilities-agent/view/vs-no</a>
Sweden	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv">https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv</a>
Spain	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-es">https://gfdplatform.pwc.lu/facilities-agent/view/vs-es</a>

This Sub-Fund is not available to retail investors in Singapore. It is accepted as restricted scheme by the Monetary Authority of Singapore (MAS) and may only be offered to certain prescribed persons on certain conditions as provided in the "Securities and Futures Act", Chapter 289 of Singapore.

This Sub-Fund is not authorised by the Securities and Futures Commission of Hong Kong. It may only be offered to those investors qualifying as professional investors under the Securities and Futures Ordinance. The contents of this document have not been reviewed by any regulatory authority in Hong Kong.

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.



# MIV Global Medtech Fund

Sub-Fund of an investment company with variable capital SICAV



## Monthly report November 2024

Marketing document for private and institutional investors

### Facts Fund class P3

Net Asset Value per Fund share USD	2'832.12
Assets USD m (all Fund classes)	2'252
Investment level	99%
Liquidity	1%

### Industry breakdown

Ophthalmology	12%
Hospital Equipment	10%
Surgical Instruments	7%
Orthopaedics	7%
Diabetes	7%
In-vitro Diagnostics	7%
Disposable Medical Supplies	6%
Endoscopy	5%
Interventional Cardiology	4%
Other Medical Technology Sectors	34%


### Holdings

Abbott Laboratories	10%	ResMed	3%
Stryker	10%	IDEXX Laboratories	3%
Boston Scientific	10%	GE HealthCare	3%
Intuitive Surgical	10%	DexCom	3%
Medtronic	5%	CooperCompanies	2%
EssilorLuxottica	4%	Steris	2%
Alcon	4%	Align Technology	2%
Edwards Lifesciences	4%	Insulet	2%
Becton Dickinson	4%	Hologic	2%
HOYA	4%	13 small holdings	14%

### Currency breakdown

USD	78%	JPY	5%
CHF	8%	DKK	2%
EUR	6%	GBP	2%

### Performance Fund class P3 USD



### Important legal information

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

### Performance in USD

	November	2024	1 year	3 years	5 years	10 years	Inception
MIV Global Medtech Fund P3	3.5%	11.8%	19.5%	-4.1%	23.4%	138.6%	187.0%
Benchmark *	3.2%	13.5%	21.1%	1.0%	38.3%	181.5%	251.9%
MSCI World Index	4.6%	21.8%	27.8%	28.7%	79.5%	160.8%	189.7%
			12.19-11.20	12.20-11.21	12.21-11.22	12.22-11.23	12.23-11.24
MIV Global Medtech Fund P3			13.1%	13.8%	-21.6%	2.3%	19.5%
Benchmark *			20.2%	13.9%	-19.1%	3.1%	21.1%
MSCI World Index			14.5%	21.8%	-10.9%	13.0%	27.8%

\* MSCI World Healthcare Equipment & Supplies

### Company Headlines

At the beginning of November, Donald Trump was elected as the new US president. He has appointed Robert F. Kennedy as Health Secretary. Kennedy has raised eyebrows in the past and during the election with controversial statements on vaccination and the pharmaceutical – but not the medical devices – industry. Generally speaking, medtech is not so much in the focus of politicians as the pharmaceutical industry, as the latter generates a much larger portion of healthcare costs, is regulated more strictly via an approval process and patents and regularly attracts attention with substantial price increases. In contrast to migration and economic policy, health is not a key topic for Donald Trump. During his administration we therefore do not anticipate any major reforms for health policy in general or any negative consequences for the medical device industry in particular. During Trump's first term in office, the medtech industry also showed that it was able to react flexibly to new customs duties.

US-based **Stryker** again beat expectations with its results for the third quarter of 2024, which were published at the end of October. Both Orthopaedics and MedSurg (hospital equipment, endoscopy, surgical instruments) & Neurotechnology produced impressive performances. Organic revenue growth amounted to 11.5%, with increased volumes contributing 10.3 percentage points and higher prices 1.2 percentage points. Management highlighted the high patient volumes, continued strong demand in the area of hospital equipment and the record number of interactive Mako robotic arm installations. Stryker's strong level of innovation has enabled it to steadily improve its market share over the years, thus achieving above-average growth rates. The firm is in an attractive product cycle with numerous launches. The forecast published in January for organic revenue growth of 7.5% to 9.0% was improved to between 9.5% and 10% by October. The growth bandwidth for adjusted earnings per share was increased to between 13% and 14%, which should equal the strong previous year.

**GE Healthcare Technologies**, based in Chicago, Illinois, was spun off as an independent company from General Electric in January 2023. It offers a wide range of medical imaging solutions, patient monitoring systems and pharmaceutical diagnostics. During the reporting month it presented its growth strategy and targets for the three-year period to 2028 at its Investor Day in New York City. CEO Peter Arduini and CFO Jay Saccaro emphasised the significance of innovation and digital solutions, particularly in the field of artificial intelligence (AI) and cloud technologies. The targets include annual organic revenue growth in the mid-single-digit range, considerable margin increases and a rise in earnings in the high single-digit to low double-digit percentage range. The plan is to use the very attractive cash flow for value-adding measures.

## Investments in medical devices

### Investment Strategy

The MIV Global Medtech Fund invests globally in listed medical device companies. The investment process is based on a combined top-down / bottom-up approach. Against the background of the particular macroeconomic environment, the most interesting markets and companies are determined based on an intensive primary analysis. Alongside an attractive valuation, a strong market position, good growth potential, excellent products, sustainable profitability and high-quality management are the decisive parameters for investment. The consideration of sustainability criteria (ESG) is integrated in the research, analysis and investment process. Risks are managed by means of portfolio diversification. The portfolio of the MIV Global Medtech Fund is structured more defensively or cyclically in the best possible anticipation of economic trends, with a view to achieving a higher return than the benchmark and the general market indices.

### Benefits

Owing to demographic trends and the desire for quality of life and mobility, the medical device industry is a long-term growth market. Emerging markets will have a positive impact on the medical device industry's future growth thanks to the state-backed expansion of their healthcare systems. Medical device suppliers' priority is the development of innovative, minimally invasive products. These are beneficial for patients and cost efficient for the healthcare system due to shorter convalescence periods. Most interesting from an investor's perspective are the industry's high growth rates, above-average profitability and oligopolistic market structures with their high entry barriers for new competitors. Even in a demanding environment, significant product innovations continue to offer attractive growth prospects.

### Risks

The MIV Global Medtech Fund invests in equity securities and may therefore be subject to high fluctuations in value. For this reason, a medium-term to long-term investment horizon and corresponding risk tolerance and capacity are required for an investment into this Sub-Fund. As the MIV Global Medtech Fund pursues an active management style, the Sub-Fund's performance can deviate substantially from that of its reference index. The focus on equity securities of global medical device companies potentially exposes the Sub-Fund to additional sector-specific risks and currency risks. The Sub-Fund may, for the purpose of hedging and the efficient management of the portfolio, make use of derivatives, which can lead to additional risks (particularly counter party risk). All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions.

### Sustainability profile - ESG

MIV Asset Management identifies, monitors and mitigates ESG risks that are, or could become, material to the performance of medical technology companies. The approach is based on the following factors:

- **Integration:** The consideration of sustainability criteria (ESG) is integrated into the research, analysis and investment process. The Fund invests in companies with a good ESG profile. The Fund does not invest in companies with a Sustainalytics ESG Risk Rating above 40 (severe) as well as a Sustainalytics Controversy Score above 4 (high).
- **Exclusion:** The Fund excludes investments in companies, that are not compliant with global norms (OECD Guidelines for Multinational Enterprises, UN Guiding Principles for Business and Human Rights, International Labour Organization's Fundamental Principles) as well as investments in controversial industries (particularly conventional and controversial weapons).
- **Sustainable Investments:** A minimum portion of 33% of assets is invested in Sustainable Investments with a social objective (contribution to UN Sustainable Development Goals).
- **Dialogue:** Close and regular contact with the management of actual and potential investments, amongst other, with the goal of improving ESG practices and disclosure at these companies.
- **Ownership rights:** Exercise of MIV Global Medtech Fund's voting rights delegated to the ISS proxy with Sustainability Policy. In case of controversial decisions, MIV Asset Management gets directly involved.

- ☑ The MIV Global Medtech Fund is classified as a financial product under **EU SFDR Article 8**
- ☑ MIV Asset Management is a signatory to the **UN Principles for Responsible Investment**
- ☑ The MIV Global Medtech Fund's investments support **UN Sustainable Development Goals, in particular no. 1, 3, 5, 8 and 10**
- ☑ MIV Asset Management works together with the **proxy ISS with Sustainability Policy**
- ☑ The MIV Global Medtech Fund has an **above-average MSCI ESG Score (6.5) and MSCI ESG Rating (A)**
- ☑ The MIV Global Medtech Fund has an **above-average Sustainalytics ESG profile**

### Glossary

Benchmark	An index, which is used as a reference for the measurement of the performance of the Fund.
Inception	Launch date of the Fund and/or the Fund class.
Management fee	Portfolio manager's fee for the management and the distribution of the Fund.
NAV	Net Asset Value: total Fund assets divided by total number of Fund shares outstanding.
TER	Total Expense Ratio: sum of all fees and costs, which are charged to the Fund on a continuous basis.

## Investments in medical devices

### Information

Website	<a href="http://www.mivglobalmedtech.com">www.mivglobalmedtech.com</a>
Legal structure	Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law
Fund class	<b>P3</b> (USD) accumulation / ISIN: LU0969575561 / Swiss Valor Number: 22479642 / WKN: A1W6X2
Subscription/redemption	On every bank working day in Luxembourg until 3.45 p.m. at net asset value (no calculation of net asset values on bank/stock exchange holidays in Luxembourg and/or the US)
Management fee	1.4% p.a.
Total Expense Ratio (TER) as of 30.6.2024	1.57%
Launch of fund	11 March 2008
Launch of fund class P3	21 October 2013
Close of financial year	30 June
Benchmark	MSCI World Healthcare Equipment & Supplies
Reporting of the Portfolio manager	Monthly, semester and yearly report
Fund price monitoring	<a href="http://www.mivglobalmedtech.com">www.mivglobalmedtech.com</a> / <a href="http://www.swissfunddata.ch">www.swissfunddata.ch</a> / <a href="http://www.fundinfo.com">www.fundinfo.com</a> Bloomberg: VARP3US LX / Reuters: LU0969575561.LUF / Neue Zürcher Zeitung
Portfolio manager	MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, <a href="mailto:info@mivglobalmedtech.ch">info@mivglobalmedtech.ch</a> Contact: Christoph Gubler, Giuseppe Di Benedetto, Christoph Gretler, Phone +41 44 253 64 11
Management company	Vontobel Asset Management S.A., 18, rue Erasme, L-1468 Luxembourg
Representative for Switzerland	Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich
Custodian/Administrator	State Street Bank International GmbH, 49, Avenue J.F. Kennedy, L-1855 Luxembourg
Auditor	Ernst & Young S.A., 35E, Avenue J.F. Kennedy, L-1855 Luxembourg
Minimum subscription	none
Admissions to distribution	Switzerland, Germany, Austria, Liechtenstein, Luxembourg, France, Italy, Spain, Finland, Norway, Sweden, Singapore (restricted scheme)
Distribution restrictions	USA / US persons

### Important legal information

MIV Global Medtech Fund is a Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law. This document is for information purposes only and nothing contained in this document should constitute a solicitation, or offer, or recommendation, to buy or sell any investment instruments, to effect any transactions, or to conclude any legal act of any kind whatsoever. This document has been produced by MIV Asset Management AG. It is explicitly not the result of a financial analysis and therefore the "Directives on the Independence of Financial Research" of the Swiss Bankers Association is not applicable. Although MIV Asset Management AG believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report. Any companies described in this document may or may not currently represent a position in the portfolio of the MIV Global Medtech Fund. Any projections, forecasts or estimates contained in this document are based on a variety of estimates and assumptions. There can be no assurance that the estimates or assumptions made will prove accurate, and actual results may differ materially.

Subscriptions of shares of the Sub-Fund should in any event be made solely on the basis of the current sales prospectus, the current Key Information Documents (KIDs), the current articles of association and the most recent annual and semi-annual reports of Variopartner SICAV. For more details regarding the potential risks of an investment in Sub-Funds of Variopartner SICAV, please refer to the current sales prospectus. Interested parties may obtain the abovementioned documents free of charge from the portfolio manager: MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, the representative for Switzerland: Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich, the paying agent in Switzerland: Bank Vontobel AG, Gotthardstrasse 43, CH-8022 Zurich, the European facilities agent for Germany, Finland, France, Italy, the Netherlands, Norway, Sweden and Spain: PwC Société coopérative – GFD, 2, rue Gerhard Mercator B.P. 1443, L-1014 Luxembourg, [lu\\_pwc.gfd.facsvs@pwc.com](mailto:lu_pwc.gfd.facsvs@pwc.com), the financial and central agent in France: BNP Paribas S.A., 16, Boulevard des Italiens, F-75009 Paris, the Austrian Facility: Erste Bank der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna, the information agent in Liechtenstein: LLB Fund Services AG, Äulestrasse 80, FL-9490 Vaduz, the paying agents in Italy: Banca Sella Holding S.p.A., Piazza Gaudenzio Sella, 1, I-13900 Biella, Allfunds Bank, S.A.U., Via Bocchetto, 6, I-20123 Milan, and from the offices of the Fund: Variopartner SICAV, 49, Avenue J.F. Kennedy, L-1855 Luxembourg. They may also be downloaded from the website [www.mivglobalmedtech.com](http://www.mivglobalmedtech.com).

Further information on the distribution of the fund's shares in an official language of the respective distribution country can be found on the corresponding website:

Germany	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-de">https://gfdplatform.pwc.lu/facilities-agent/view/vs-de</a>
Finland	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fi</a>
France	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr">https://gfdplatform.pwc.lu/facilities-agent/view/vs-fr</a>
Italy	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-it">https://gfdplatform.pwc.lu/facilities-agent/view/vs-it</a>
Netherlands	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl">https://gfdplatform.pwc.lu/facilities-agent/view/vs-nl</a>
Norway	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-no">https://gfdplatform.pwc.lu/facilities-agent/view/vs-no</a>
Sweden	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv">https://gfdplatform.pwc.lu/facilities-agent/view/vs-sv</a>
Spain	<a href="https://gfdplatform.pwc.lu/facilities-agent/view/vs-es">https://gfdplatform.pwc.lu/facilities-agent/view/vs-es</a>

This Sub-Fund is not available to retail investors in Singapore. It is accepted as restricted scheme by the Monetary Authority of Singapore (MAS) and may only be offered to certain prescribed persons on certain conditions as provided in the "Securities and Futures Act", Chapter 289 of Singapore.

This Sub-Fund is not authorised by the Securities and Futures Commission of Hong Kong. It may only be offered to those investors qualifying as professional investors under the Securities and Futures Ordinance. The contents of this document have not been reviewed by any regulatory authority in Hong Kong.

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.